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ABSTRACT 
 
 The multidisciplinary field of nanotechnology has allowed for unprecedented 
exploration and manipulation of molecular, sub-molecular, and atomic structures and 
advancements in this field are revolutionizing scientific thought and applications. Within 
the field of nanotechnology, the branch of nanobiotechnology focuses on studying the 
effects of nanomaterials on biological systems and to elucidate how nanomaterials 
interact with cells and cellular components. Nanoparticles are a particular type of 
nanomaterial whose dimensions measure 100 nanometers and are shown to possess 
unique size-dependent physical, chemical and biological properties compared to their 
bulk counterparts. Metal oxide nanoparticles, such as those made from ZnO, are a type of 
nanomaterial found in many different industrial products such as sunscreen, food 
preservatives and clothing. Due to the prevalence of ZnO nanoparticles in the 
environment, there is an urgent need to gain an understanding of how these particles 
interact with biological systems, and due to the fact that nanoparticles are within the 
range of many different naturally occurring biological molecules, research investigating 
nanoparticle-cell interactions may offer innovative approaches for the development of 
novel biomedical applications. 
 This research focuses on examining the effects of metal oxide based 
nanoparticles, including ZnO, on immune cells and investigates cell-specific responses 
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and mechanisms of toxicity.  Collectively, our results demonstrate differential ZnO NP 
toxicity based on cell-type, activation status, and NP size with highly proliferative/rapidly 
diving cells (e.g. cancer cells and activated T cells) killed at lower concentrations of ZnO 
nanoparticles compared to normal cells. In addition, an inverse relationship between 
nanoparticle size and cytotoxicity was observed. Further, these results implicate ROS 
production as a major mechanism of ZnO-NP induced cytotoxicity capable of inducing 
apoptosis in human immune cells, and reveal ZnO NP induce pro-inflammatory cytokine 
production (e.g. IFN-, TNF-α and IL-12). Exploitation of the preferential nanoparticle-
mediated toxicity observed in these studies may provide a foundation for the design and 
development of novel ZnO nanoparticle based biomedical applications and therapeutics 
for the treatment of human diseases, such as cancer and autoimmune disorders.    
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INTRODUCTION 
 
 Scientific advancements in biology and biotechnology have enabled the molecular 
and sub-molecular examination of intracellular dynamics and intercellular interactions, 
resulting in the development of new and improved biomedical devices and therapeutic 
interventions. The ability to investigate sub-atomic, atomic and molecular materials and 
structures has led to the emerging field of nanotechnology, a multidisciplinary industry 
concerned with researching, developing and utilizing nanometer (nm) sized materials. As 
many naturally occurring biological structures are found in the nanometer range, the 
integration of biology and nanotechnology provides a platform by which significant 
contributions to the development of new diagnostic agents and devices, and targeted 
therapeutic treatments may be achieved. Nano-sized materials, such as nanoparticles 
(NP), can exhibit unusual properties such as alterations in chemical reactivity and other 
physical characteristics not predicted for larger particles made from the same material 
(Feringa 2000). The altered properties of NP, coupled with their similarity in size to 
many biological structures, allow for their interactions with biomolecules both on the cell 
surface and within the cell, and may potentially affect cellular responses in a dynamic 
and selective manner. As such, it is necessary to identify and characterize the effects of 
NP on various biological systems and cell types and evaluate the possibility of exploiting 
NP for use in novel biomedical applications.
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Nanotechnology and Nanomaterials 
 Nanotechnology encompasses many different scientific disciplines, including 
computer science, engineering, physics, chemistry and biology, and has revolutionized 
scientific applications in all these areas. Explosive growth in the field of nanotechnology 
has resulted in phenomenal global market spending on research and products, increasing 
from $8.6 billion in 2004 to upwards of $18 billion in 2008 (approximately $8.4 billion in 
government funding, $8.4 billion in corporate funding and $1.6 billion in venture 
capitalist funding), and is estimated to exceed more than $2.5 trillion dollars worldwide 
by the year 2014 (Lux Research Inc 2009). In response to this rapid growth and the 
widespread use of nano-based products, federally funded organizations, such as the 
National Nanotechnology Initiative (NNI), have been created to monitor and support the 
research and development of nanomaterials and nanostructures. As stated in the White 
House press release upon the formation of the NNI, ―These developments [in 
nanotechnology] are likely to change the way almost everything - from vaccines to 
computers to automobile tires to objects not yet imagined - is designed and made‖ (NNI 
2009).   
 Unlike bulk materials, whose behaviors are dictated and predicted based on the 
laws of classical physics and the properties of individual molecules, the properties and 
characteristics of nanomaterials are governed by laws of both quantum and classical 
physics. This phenomenon is attributed to ―quantum effects‖ in which the behaviors of a 
materials are altered in response to significant reductions in material size (Singh and 
Nalwa 2007). As the size of a material is reduced to the nano-scale, there is an increase in 
the surface area to volume ratio, and a greater percentage of atoms are expressed on the 
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surface of nanomaterials compared to micron-sized bulk materials (Cao 2004). The 
consequences of this phenomenon are the unique properties observed in many 
nanomaterials such as changes in reactivity, conductivity, and light diffraction. An 
example of these changes is illustrated when comparing the properties of bulk copper 
compared to nano-sized copper structures. Although bulk copper (e.g. wire, ribbon, etc.) 
is malleable and highly conductive, when reduced to the nano-scale (less than 50 nm) 
copper loses both its malleability and conductive abilities (Takata, Lee, Lim, Kim and 
Tsuji 2007). Another example is the discrepancy observed in suspensions of alumina NP, 
which have been shown to have increased thermal conductivity compared to suspensions 
of micron-sized alumina particles (Oesterling et al. 2008).   
 The term ―nanotechnology‖ is a 20th century idiom, however evidence for 
utilization of nanomaterials can be found in early civilization artifacts. Archaeologists 
and museum scientists have discovered that 10
th
 century Persian artisans used metallic 
(e.g. silver and copper) NP in ceramic glazes to give the pottery an illustrious and 
iridescent finish, with results dependent on size, shape, and the distribution of the 
metallic clusters in the glaze (Erhardt 2003). This technique, which spread throughout 
Europe by the 14
th
 century, was accomplished by the breakdown of metal salts and oxides 
during the firing process (Erhardt 2003). Although the molecular basis for the distinctive 
properties exhibited by these nanomaterials (namely, increased optical refractivity and 
surface reactivity) was not understood at the time, modern science has revealed these 
desirable qualities are ascribed to the nanometer-sized particles found in these glazes.  
 The central scientific concepts which led to the creation of nanotechnology were 
first described by Scottish physicist, James Clerk Maxwell, in 1867, whose work 
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revolutionized theories explaining the laws of thermodynamics and electromagnetic 
behavior (Maxwell and Niven 2003). His theories, stating that molecular movement is 
predicted by the laws of probability, and not certainty, created a foundation upon which 
nanotechnology was developed (Maxwell and Niven 2003). From that time through the 
first quarter of the 20
th
 century, significant progress was made towards the understanding 
of atomic/sub-atomic behavior, all of which contributed to the concepts upon which 
nanotechnology is built. However, it was a seminar given by Richard Feynman in 1959 
entitled ―There’s Plenty of Room at the Bottom‖ which is credited as catalyzing the 
creation of nanotechnology (Wilkinson 2004). In this presentation, Dr. Feynman 
discussed the possibility of manipulating materials at the atomic and molecular scale, and 
addressed the potential issues associated with this, such as the fact that matter on this 
scale behaves differently than it would on a larger scale (Feynman 1959).  
 Nanomaterials and nano-based products are becoming increasingly prevalent and 
can already be found in a variety of different industrial applications, ranging from 
electronics and laser-based applications to anti-microbial band-aids and anti-reflective 
coatings for glass (Osman, Rardon, Friedman, and Fanor-Vega 2006). Specific types of 
nanomaterials, such as those made from metal oxides, have been found to possess 
specific properties, such as increased conductivity, changes in color and transparency, 
which make them useful in a wide-range of industrial products, including water-repellent 
clothing, biosensors, electronics and cosmetics (Cao 2004).  
ZnO is a type of naturally occurring metal oxide frequently found in a variety of 
different products such as paints, adhesives, sunscreens, cosmetics, and as an anti-
microbial agent in ointments and rubber (Nohynek, Dufour and Roberts 2008). When 
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reduced to the nano-scale, ZnO exhibits distinctive optical and electronic properties, and 
demonstrates superior transparency and UV adsorption/blocking abilities compared to 
bulk ZnO (Cross, Innes, Roberts, Tsuzuki, Robertson and McCormick 2007). Due to the 
increasing use of nanomaterials in industrial applications, a thorough understanding of 
the mechanisms by which nano-sized materials interact and impact various cell types is 
critical from both a toxicological standpoint and for enabling the discovery of potential 
applications for these materials.  
 
Nanobiotechnology and Nanoparticles 
 Nanobiotechnology is a specific branch of nanotechnology aimed at investigating 
potential biological applications for nanomaterials and exploring how nano-sized 
materials and structures interact with and affect biological systems (McNeil 2005). As 
many important biological entities, such as DNA and proteins, fall within the nanometer 
size range, nanomaterials (e.g. NP) are being designed to interact with specific biological 
components allowing for improved precision and efficiency in molecular manufacturing 
and control. The use of nanomaterials in biological applications may provide new 
approaches and exciting possibilities for genomics, information storage, energy 
conservation and medicine. Current applications under investigation include biosensing, 
tumor imaging, and targeted drug delivery (e.g. antibody-NP conjugates) (Angeli et al. 
2008; Dinauer, Balthasar, Weber, Kreuter, Langer and von Briesen 2005). Researching 
new applications for different types of nanomaterials in a biological context is an integral 
part of nanobiotechnology, and exploiting the specific properties of nanomaterials may 
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enable new approaches for manipulating and eliciting specific biological responses 
(Lowe 2000).  
 NP (particles 100 nm or less in any two dimensions) are among the nanomaterials 
that may be best suited for biological applications due to their size being in the range of 
many biological entities and their unique size-dependent properties (Zhang, Gu, Chan, 
Wang, Langer and Farokhzad 2008). NP are highly diversified, come in a variety of 
different shapes and sizes and are made from an assortment of materials. All these factors 
contribute to the unique size-dependent physical, chemical, and biological properties 
observed in NP which distinguish them from their micron-sized bulk counterparts 
(McNeil 2005). Additionally, many types of NP have a propensity to form micrometer-
sized aggregates (called nanopowders), which affect both the solubility and behavior of 
these materials (Roca and Haes 2008). Metal oxide NP, in particular, have wide-spread 
applications and are frequently found in many different commercial products ranging 
from sunscreens and cosmetics (e.g. TiO2, Fe3O4 and ZnO) to dental fillers (e.g. SiO2) 
and photovoltaic cells (e.g. CdS, CdSe and ZnS) (Brayner, Ferrari-Iliou, Brivois, Djediat, 
Benedetti and Fievet 2006; Donaldson 2006).   
 Examples of some NP dependent properties include superparamagnetism 
observed in certain types of magnetic NP, surface plasmon resonance in various metal 
NP, and the quantum confinement of semiconductor NP (Donaldson 2006). These 
differences are further illustrated in the altered characteristics observed in gold NP which 
appear reddish-black in color and are capable of conducting electricity, compared to 
micron-sized bulk gold which is yellow in color and non-conductive (Wilson 2008). The 
distinctive chemical and physical properties observed in NP warrants further 
7 
 
investigation into the biological effects of specific types of NP to various cellular systems 
and cell types under physiologically relevant conditions and identifying different types of 
NP suited for biological applications (Schmid 2004). To this end, much research is being 
conducted to evaluate potential biological applications for various types of NP, ranging 
from drug delivery and biosensing to even utilizing NP as drugs themselves (Bogunia-
Kubik and Sugisaka 2002). Examples of NP specifically useful for biotechnology and 
nanomedicine include fullerenes (e.g. bucky balls and carbon tubes), liposomes, 
nanoshells, dendrimers, nanorods, superparamagnetic NP, and quantum dots (QDs) 
(Roco 2003). 
 QDs, or nanocrystals, are semiconductor NP (e.g. CuO2, Fe2O3, Au, ZnO, etc.) 
being explored for biotechnological applications, specifically for use in biosensing, cell-
labeling/tumor imaging and drug delivery due to their distinctive electronic and 
fluorescent properties and reduced tendency to photobleach (Vashist, Tewari, Bajpai, 
Bharadwaj and Raiteri 2006).  The novel properties possessed by QDs are due to valence 
electron band holes, or excitons, which are confined in all three spatial dimensions in 
these particles (Ashammakhi 2006). As many types of metal NP and metal oxide NP are 
QDs, these NP (e.g. ZnO NP) are gaining recognition and utility not only for expansion 
on traditional applications, but also for new biomedical purposes.  
 
Nanomedicine and Biomedical Applications of NP 
  Nanomedicine is similar to nanobiotechnology in that both encompass 
investigating the impact of nanomaterials on biological systems. However, nanomedicine 
specifically describes the intersection of nanotechnology and medical science, and is 
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focused on developing and utilizing nanomaterials to target specific cellular and sub-
cellular components for disease prevention, treatment and damaged tissue repair 
(Moghimi, Hunter and Murray 2005; Ashammakhi 2006). In contrast to many 
conventional therapeutics (e.g. radiation, chemotherapy and surgery), nanomedicine 
offers highly selective approaches to eliminate or repair specific cells and examples of 
the types of nanomedicines under investigation include NP biological mimetics, the 
creation of ―nanomachines‖ (e.g. structures made from interchangeable DNA parts and 
DNA scaffolds), nano-scale devices used for drug release, biosensors for use in 
laboratory diagnosis (e.g. QD), polymetric nano-constructs for use as molecular switches, 
tissue engineering, and creating NP-antibody conjugates for targeted delivery of drugs, 
genetic elements and diagnostic agents to specific cells and tissues (Navalakhe and 
Nandedkar 2007; Riehemann, Schneider, Luger, Godin, Ferrari and Fuchs 2009). 
Additionally, NP may be useful modalities for targeting and killing specific disease 
causing cells (e.g. tumor and auto-reactive cells) while leaving normal cells and tissues 
unharmed, and with fewer adverse side effects compared to conventional treatments 
(Cho, Wang, Nie, Chen and Shin 2008).  
 Thus far, findings from several published in vitro studies examining the ability of 
engineered NP to selectively destroy disease-causing pathogens and cancer cells have 
revealed promising results (Emerich and Thanos 2007). One approach involves using 
porous, biologically compatible ceramic NP (e.g. silica, alumina, titania, etc.)  to 
encapsulate anti-cancer photosensitive drugs (Salata 2004). Cytotoxicity is achieved 
using a laser beam, which causes the photosensitive drugs to release reactive oxygen 
species (ROS) which are cytotoxic to the targeted tumor cells, and surface modifications 
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(e.g. attaching antibodies to the surface) allow targeted delivery and uptake of the 
NP/drug complex to tumor cells (Salata 2004). Exploring different types of NP materials 
for use in nanomedicines may reveal innovative methods for treating human diseases 
such as cancer, autoimmune disease, neurodegenerative disorders and infection. 
However, before any nanomedicine can be employed, a detailed understanding of how 
NP interact and effect different types of cells is critical and is one of the major goals of 
our research.   
 
NP and Toxicity 
The development and industrial exploitation of NP is progressing at an extremely 
rapid rate and potential applications are being continually discovered. However, 
information regarding mechanisms of NP toxicity to different cell types and biological 
systems lags behind this prolific growth. Understanding the effects of NP on cell systems 
is imperative as the unique behaviors and characteristics observed in many nano-sized 
materials can potentially render an otherwise benign substance toxic to cells at the same 
concentration (Nair et al. 2008). For example, a recently published study showed CdS NP 
to be toxic to mammalian Chinese Hamster Lung (CHL) cells at lower concentrations 
compared to micron sized CdS particles (Li et al. 2009). As with the introduction of any 
new material that displays unusual and unorthodox behaviors, there is a need to increase 
knowledge and awareness of the potential environmental impacts and toxic effects. The 
toxicity of a given substance is monitored and recorded by the Federal Drug 
Administration which has established a list of ―Generally Recognized as Safe‖ (GRAS) 
substances which is a record of substances shown by rigorous in vitro and in vivo 
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scientific studies to be safe under the conditions of their accepted use and are thus exempt 
from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance 
requirements (Angeli et al. 2008).  Lately, concern has been raised over the evaluation 
guidelines used to assess the safety of commonly accepted nano-sized GRAS substances, 
as most toxicological data collected  was conducted using bulk sized materials and did 
not take the special characteristics of nanomaterials into consideration (Fischer and Chan 
2007). Recently published research suggests NP toxicity is largely dependent on chemical 
composition (e.g. subsequent ion dissolution and NP catalyzed cell-surface reactions), 
potential for ROS formation, NP size/shape, and specific NP-cell interactions (Guo et al. 
2008; Dobrovolskaia and McNeil 2007). As such, additional research is needed to 
investigate the factors influencing NP toxicity to specific cell types and to elucidate 
mechanisms of NP-induced cytotoxicity.  
 Although ZnO is a GRAS substance and has been shown to be relatively nontoxic 
in bulk form (micron-sized particles and larger), recently published studies have 
demonstrated ZnO NP toxicity in both eukaryotic and prokaryotic cell types. In one 
study, researchers tested the effects of various metal oxide NP (e.g. TiO2, Al2O3, SiO2 
and ZnO) to several strains of bacteria (E. coli, B. subtilis and P. fluorescens) and found 
significant differences in toxicity in all metal oxide NP tested (except for TiO2) compared 
to their respective micron-scaled counterparts. Interestingly, of all the metal oxide NP 
types used in this study, ZnO NP were shown to be the most toxic to all bacterial strains 
tested (Jiang, Mashayekhi and Xing 2009). Another recently published study found ZnO 
NP display selective toxicity to different bacterial strains, namely increased susceptibility 
in S. aureus compared to E. coli. In addition, this study demonstrated that prokaryotic 
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cells were killed at lower concentrations of ZnO NP compared to primary human T cells 
(Reddy, Feris, Bell, Wingett, Hanley and Punnoose 2007).  
Other published studies examining the effects of metal oxide NP, specifically 
ZnO NP, on eukaryotic cells have demonstrated significant cytotoxicity in various 
mammalian cells, and research suggests the production of ROS may be a predominant 
mechanism of toxicity (Limbach, Wick, Manser, Grass, Bruinink and Stark 2007). In 
order to better predict toxic potential of NP due to oxidative stress, the hierarchical 
oxidative stress model was developed which uses a three-tiered system based on the 
levels of ROS produced in response to ZnO NP, CeO2 NP and TiO2 NP (Xia et al. 
2008a). In tier 1, low levels of ROS produced initiate the upregulation of the Nrf2 
transcription factor responsible for mediating the expression of antioxidant response 
elements (ARE) in promoter phase 2 genes. This chain of events acts as a compensatory 
mechanism to protect against ROS-induced cell damage. If exogenous sources of ROS 
overwhelm tier 1 mechanisms, an inflammatory response is elicited in which ROS induce 
redox-sensitive signaling pathways (e.g. MAP-kinases, NF-B cascades and pro-
inflammatory cytokine expression such as IL-12, IFN- and TNF-α). Finally, if ROS are 
produced in excess of what is required to induce a tier 2 response, mitochondrial inner 
membrane electron transfer and permeability are disrupted, resulting in ROS-induced cell 
death by both apoptotic and necrotic pathways. 
Although ZnO NP have been shown to be toxic to eukaryotic cells, the majority 
of research testing the ZnO NP toxicity to mammalian cells has been done on 
immortalized cell lines and up until now, there have been only limited in vitro studies 
evaluating ZnO NP cytotoxicity to primary human cells. Additionally, little is known 
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about the factors influencing ZnO NP-mediated toxicity to specific immune cell types 
such as ROS formation and mechanisms of ZnO NP-induced cell death (e.g. apoptosis 
and necrosis). ZnO toxicity to both eukaryotic and prokaryotic cells has been established, 
with varying toxicity thresholds observed for different strains of bacteria. Given the 
integral role of the immune system in treating and preventing disease and maintaining 
host integrity and the phenotypic diversity present amongst immune cells, it is reasonable 
to assume not all immune cells will respond the same to ZnO NP treatment and is an 
issue that requires further examination. 
 
The Immune System and Host Health 
The immune system acts to protect and defend animals from pathological, 
potentially disease-causing entities such as viruses, bacteria, parasites, and 
mutated/aberrant cells (i.e. cancer cells) by means of highly complex and tightly 
regulated physical, chemical and biological mechanisms (U.S. Department of Health and 
Human Services 2003). A key aspect of the immune system is the ability to distinguish 
―self‖ from ―nonself‖, or put another way, the ability to recognize and ignore normal 
healthy ―self‖ cells and to identify and destroy ―foreign‖ non-self cells and entities 
(Mannie 1999). This requires the coordinated action of many different types of cells 
called leukocytes, commonly known as ―white blood cells‖ (WBC). Immune system 
malfunctioning results in the emergence of disease-processes such as autoimmune disease 
(where the immune cells attack and destroy normal healthy tissue) or in the case of 
immune system failure, the emergence of opportunistic infections and cancer (Cohn 
2005). Evaluating the effects of commonly used NP, such as ZnO NP, on immune cells 
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and elucidating mechanisms of immune cell-NP interactions may ultimately allow for 
creating targeted NP treatments for these diseases and provides critical information on 
how ZnO NP impact the human immune system.  
 
Innate Versus Adaptive Immunity 
The immune system is broadly broken up into two intricately related groups, 
innate immunity and adaptive immunity (Huston 1997). Innate immunity refers to those 
defense mechanisms which serve as the ―first line of defense‖ against foreign entities 
upon initial exposure. Components of the innate immune system are preventive in nature 
and are present before exposure to an infectious pathogen and are extremely fast in nature 
(Uthaisangsook, Day, Bahna, Good and Haraguchi 2002). An important distinction 
between innate and adaptive immune response is that innate immune mechanisms are 
non-specific, as they do not recognize specific pathogens but rather provide general 
barriers against infection or recognize general classes of molecular markers commonly 
found on classes of pathological organisms (Uthaisangsook et al. 2002). Examples 
include physical barriers such as the skin and mucous membranes, physiological barriers 
such as temperature and pH, and biological barriers by way of cells that act to contain 
and/or destroy pathogens and small non-cellular debris via internalization and the release 
of various chemicals and cytokines (Mayer 2006). Additionally, the inflammatory 
response acts as a barrier against foreign invasion by containment, activation, and 
recruitment of immune cells to the area of infection (Mayer 2006).  
When cells of the innate immune system recognize general ―foreign‖ proteins 
they respond by either engulfment and intracellular destruction of the foreign material 
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(called phagocytosis), or by direct killing processes using chemicals mediators injected 
into target cells (Mayer 2006). After phagocytosis of a pathogen has occurred, a piece of 
the pathogen (an antigen (Ag)) is expressed on the phagocyte cell surface in a process 
known as Ag-presentation (Mayer 2006). Certain immune cells, namely dendritic cells 
(DC), macrophages/monocytes and B cells are known as professional antigen presenting 
cells (APC), and are responsible for presenting Ag to T lymphocytes (cells of the 
adaptive immune response) and activating Ag-specific immune responses (Bowers 
2006a). A crucial aspect of immune response involves the release of soluble proteins 
called cytokines by immune cells in response to their encounter with foreign Ag, which 
serve as a means of cell-to-cell communication and are critical for proper immune system 
functioning (Mulloy and Rider 2006). Cytokines recognize and bind to specific receptors 
found on the surfaces of neighboring cells (paracrine), cells located distantly (endocrine) 
or on the secreting cell itself (autocrine) (Parkin and Cohen 2001). Binding of a cytokine 
to its receptor causes cell ―activation‖, a process by which the cell progresses through the 
cell cycle, divides and proliferates and carries out various biological processes. Cells of 
the innate immune system include mast cells, eosinophils, basophils, neutrophils, DC, 
macrophages/monocytes, and natural killer (NK) cells (Mayer 2006).  
In contrast to innate immunity, adaptive immunity is highly selective and diverse, 
and is capable of immunologic memory, a process by which arsenals of ―memory‖ cells 
are formed for protection against future Ag exposure (Pancer and Cooper 2006). 
Additionally, cells of the adaptive immune response, namely T and B cell lymphocytes, 
are able to recognize and distinguish self from nonself (Pancer and Cooper 2006) and are 
capable of recognizing an infinite number of Ag (molecular markers specific to a 
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particular pathogen or foreign material) for the elimination of  cells or entities displaying 
the specific Ag (Pancer and Cooper 2006). Once a specific Ag has been encountered, 
―memory‖ cells are created and remain dormant in circulation. In the event of a second 
encounter with the same Ag, memory cells become activated and rapidly proliferate to 
mount an attack against the foreign invader (Pancer and Cooper 2006). A functional 
adaptive immune system requires cooperation between B cells and T cells. While B cells 
serve as APC and produce Ag-specific antibodies to eliminate pathogens, T cells are 
activated after recognizing Ag presented by APC (Krogsgaard and Davis 2005). 
Although cells of the adaptive immune response are slower to take effect initially, once 
activated they are powerful weapons in fighting infection and disease (Pancer and Cooper 
2006). Our research focuses on the effects of ZnO NP on T cells, B cells, NK cells and 
monocytes as a representative panel of immune cells with varying phenotypes and 
diverse biological functions. 
 
Mechanisms of Cellular-Uptake: Endocytosis and Phagocytosis 
Endocytosis describes the active (ATP-dependent) process used by cells for 
importing selected substances present in the extracellular environment (e.g. 
macromolecules, pathogens, membrane lipids, integral proteins and other particulate 
matter), and endocytic pathways are used by viruses, toxins and symbiotic micro-
organisms to gain entry into cells (Doherty and McMahon 2009). Endocytic mechanisms 
serve many important cellular functions including the uptake of extracellular nutrients, 
regulation of cell-surface receptor expression, maintenance of cell polarity, and 
preservation of host health by eliminating potentially harmful bacteria and activating the 
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immune response by Ag-presentation (Seabra, Mules and Hume 2002; Doherty and 
McMahon 2009). During endocytosis, materials are taken into the cell by invagination of 
the plasma membrane, resulting in the formation of new membrane-bound vesicles 
containing the ingested substances (called endosomes), and are transported to various 
intracellular locations including digestive organelles (e.g. lysosomes) for degradation and 
cytoplasmic storage within endocytic compartments (Doherty and McMahon 2009). 
Additionally, endocytosis can occur by both clathrin-mediated and clathrin-independent 
processes, the former which is associated with the cytosolic protein clathrin, a large 
protein that assists in the formation of clathrin-coated pits on the inner surface of the 
plasma membrane. Endocytosis is generally subdivided into three groups: pinocytosis, 
receptor-mediated endocytosis, and phagocytosis (Decuzzi and Ferarri 2007), although 
disagreement exists among scientists about how endocytosis should be classified and 
some literature describes receptor-mediated endocytosis as a type of pinocytosis and 
considers phagocytosis as a separate cellular process altogether. Almost all cells of the 
body are capable of pinocytosis (also known as fluid endocytosis), an important cellular 
function by which cells engulf a portion of the extracellular fluid and all suspended 
and/or dissolved solutes, macromolecules, and small particulate matter. Unlike receptor-
mediated endocytosis (RME), where ingestion of certain substances (e.g. cell surface 
proteins, viruses, etc.) is triggered by a ligand binding to its specific cell receptor, 
pinocytosis is non-specific as whatever substances/solutes are found within the area of 
invagination are brought into the cell from the extracellular environment (Lodish, Beck, 
Zipurksy, Matsudaira, Baltimore and Darnell 2000). RME is a highly complex and tightly 
regulated process used by most cells for the internalization of extracellular molecules 
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(e.g. proteins, viruses, transmembrane receptors, ion channels, etc.) in response to ligands 
binding to complementary cell-surface receptors and allows for precise regulation of the 
interactions between the cell and its environment. For example, regulation of cell 
sensitivity to specific extracellular ligand-mediated cues is achieved by RME, resulting in 
removal of certain transmembrane receptors so they are no longer available for these 
interactions (Doherty and McMahon 2009). Subsequent to ligand-receptor binding, 
clathrin-pits invaginate into the cell and bud off to yield ligand-receptor complexes in 
clathrin-coated vesicles (CCVs), and once transported from the cell membrane, are 
uncoated and the contents of the vesicles delivered to their target locations (Decuzzi and 
Ferrari 2008).  
Phagocytosis is a special type of actin-dependent endocytosis used by specific 
immune cells, namely neutrophils, DC and monocytes/macrophages, as a major immune 
defense mechanism for the envelopment and internalization of large foreign particulates 
(usually >250 nm in size), bacteria, dead and/or dying cells, etc. (May and Machesky 
2001). Phagocytosis requires recognition and binding of the material to specific plasma 
membrane receptors (e.g. Fc receptors, mannose receptors, scavenger receptors, etc.) 
capable of triggering intracellular uptake (usually by formation of F-actin driven 
pseudopods) of the membrane bound particle in vesicles called phagosomes. Subsequent 
to ingestion, phagosomes typically fuse with endosomes and/or lysosomes, exposing their 
contents to hydrolytic enzymes for digestion and intracellular processing of the material 
results in cell surface Ag-presentation (expression of a conserved protein sequence) on 
the phagocyte surface (May and Machesky 2001).  
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T Cells and Their Role in the Immune Response 
T cells and B cells belong to a specific group of white blood cells called 
lymphocytes (Beilhack and Rockson 2003). T cells are named after the thymus gland 
which is the tissue in which they mature, and it is here that T cells migrate (after 
originating in the bone marrow) and begin to express an Ag-specific binding receptor on 
their surface called the T cell receptor (TCR) (Medema and Borst 1999). T cells play an 
integral role in both the innate and mammalian acquired immune responses by 
coordinating and activating immune cells from both arms of the immune system against a 
specific Ag and have direct, Ag-specific cytotoxic killing abilities. T cells are unique in 
that they almost only recognize and become activated by Ag presented in the context of a 
specific type of cell-membrane molecule, called a major histocompatibility complex 
(MHC) (Hummell 1994). Once activated, T cells are responsible for a myriad of activities 
which include mounting a specific defense against the foreign pathogens, direct killing of 
virally infected cells or tumor cells, and regulation of the T cell mediated response 
(Beilhack and Rockson 2003). T cells are divided into two subpopulations: T helper cells 
(TH) and cytotoxic T cells (Tc) (Huston 1997). TH cells express a CD4 receptor on their 
surface and are thus named CD4
+
 T cells, while TC cells express a CD8 receptor and are 
named CD8
+
 T cells. CD4
+
 TH cells recognize Ag presented in the context of MHC II, a 
protein found on the surface of APC cells, while CD8
+
 TC cells recognize Ag presented 
by MHC I, a protein found on all nucleated cells (Medema and Borst 1999). TC cells 
possess direct cytotoxic capabilities toward virally infected cells and cancer/tumor cells 
and are the cells involved in tissue rejection after transplantation (Behrens et al. 2004).  
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Additionally, all T cells are defined as either memory T cells or naïve T cells, a 
classification based on prior exposure to a specific Ag (Surh and Sprent 2008).  
 
CD4
+
 T Helper (TH) Cells 
T helper cells (TH) comprise a subset of T lymphocytes responsible for 
orchestrating the immune response (Cohn 2005) and are also referred to as CD4
+
 T cells 
due to the expression of a membrane glycoprotein molecule found on their surface called 
the cluster of differentiation (CD) type 4 (Schepers, Arens and Schumascher 2005). 
Unlike other types of immune cells, TH cells are unique in that they do not phagocytose 
and/or have any direct cytotoxic abilities (Behrens et al. 2004) but instead are capable of 
recognizing Ag presented in the context of MHC class II proteins found on the surface of 
APCs, namely B cells, DCs and macrophages/monocytes (Krogsgaard and Davis 2005). 
Once TH cells bind to the Ag-MHC II complex, they release numerous cytokines which 
bind to specific receptors located on the membranes of various cell types, and activate 
and direct immune cell activity involved in inflammation and pathogen elimination 
(Wieder, Braumuller, Kneilling, Pichler and Rocken 2008). In addition to activating a 
host of different immune cells, cytokines direct the differentiation of T helper cells into 
two different subsets, type 1 (Th1) and type 2 (Th2) (Fishman and Perelson 1999).  
 
Th1 Versus Th2  
Activated TH cells secrete various cytokines which result in the activation and 
proliferation of other immune cells and initiate differentiation of T helper cells into two 
classes, Th1 and Th2 (Bowers 2006b). Th1 and Th2 differ in the cytokines they secrete, 
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which impacts the type of immune response produced, either a humoral, B-cell/antibody-
based response, or a cellular, inflammatory-based response (Bowers 2006b). Th1 
induction occurs in the presence of IL-2 and TNF-, cytokines secreted mainly from 
macrophages/monocytes and DC (Fishman and Perelson 1999) and stimulate cells 
involved in the inflammatory response (e.g. macrophages/monocytes, DC and NK) to 
proliferate and secrete pro-inflammatory cytokines such as IL-12, IFN-gamma, etc. (Guo 
et al. 2004) At the same time, Th1 cells inhibit the production of IL-4, a major cytokine 
involved in promoting Th2 differentiation, thereby preserving and maintaining the Th1 
response (Fishman and Perelson 1999).  
The primary function of Th2 cells is to stimulate B cell proliferation and induce 
B-cell antibody class switching resulting in increased antibody production against a 
particular pathogen (Liberman, Refojo and Arzt 2003; Kondo 2003). The cytokines 
secreted by Th2 cells (e.g. IL-4, IL-5, IL-6, IL-10 and IL-13) serve to activate B cells and 
maintain the Th2 response by inhibition of cytokines critical for Th1 differentiation and 
result in Ag elimination and clearance of invading pathogens from the host (Sallusto, 
Palermo, Hoy and Lanzavecchia 1999; Fishman and Perelson 1999).  
 
Memory Versus Naïve T Cells   
 T cells clones of antigenically-stimulated cells are called memory T cells, while T 
cells that have not yet encountered peripheral cognate Ag are called naïve T cells (Surh 
and Sprent 2008) and these T cell subsets are distinguished from each other based on 
their response to Ag and expression of specific cell surface markers. Memory T cells, 
characterized by the expression of the cell surface marker CD45RO (CD45RO
+
), persist 
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after Ag exposure and remain dormant and inactive until a secondary encounter takes 
place (Surh and Sprent 2008). Unlike memory T cells, naïve T cells (Th0) have not 
encountered cognate Ag, and are non-prolific quiescent cells characterized by the 
expression of the cell-surface marker CD45RA (CD45RA
+
 cells) (Zimmermann, Prevost-
Blondel, Blaser and Pircher 1999). Naïve T cells circulate throughout the body in a state 
of homeostasis until encounter with novel Ag, and upon activation adopt an activated or 
―memory‖ phenotype.  The process of aging skews the memory to naive T cell ratio in 
favor of memory cells, which is partly responsible for the reduced ability of geriatric 
populations to effectively fight infection and disease (Surh and Sprent 2008). Both 
memory and naïve T cells are critical elements of the immune response; memory T cells 
allow for a fast response to previously encountered Ag, while naïve T cells are slower to 
respond, but enable the host to fight novel pathogens.  
 
                                                 T Cell Activation 
All mature T cells express the T cell receptor (TCR) on their surface, which is 
required for the ability of T cells to recognize and respond to Ag presented by APCs 
(Rojo, Bello and Portoles 2008). Each TCR is composed of two transmembrane 
polypeptides,  and  or and , with  bearing T cells being the more common type 
(Modlin and Sieling 2005).  Each TCR subunit has one variable and one constant domain, 
and at the end of each TCR are hypervariable loops that recognize Ag presented by MHC 
(Godfrey, Rossjohn and McCluskey 2008). Additionally, each TCR molecule is 
associated with a molecule called CD3, a complex critical for T cell signal transduction, 
made up of five transmembrane polypeptides (, , , , and ) which come together to 
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form three dimers (, , and or (Rojo et al. 2008).  A correctly assembled TCR-
CD3 complex is essential for T cell activation since the TCR is necessary for recognition 
of Ag (Feito, Jimenez-Perianez, Ojeda, Sanchez, Portoles and Rojo 2002).  TCRs are 
capable of distinguishing self from non-self through the recognition of both endogenous 
(i.e. tumor cells and virally infected cells) and exogenous (i.e. bacteria) foreign 
molecules. Upon pathogen recognition, APCs engulf and digest the foreign material into 
smaller peptides which are expressed on the surface of the APC in the context of a MHC 
molecule, and circulating T cells are able to recognize and bind to foreign peptide/MHC 
complexes, resulting in T cell activation and subsequent pathogen clearance (Lindquist 
and Schraven 2006).  
 CD28 is a surface molecule constitutively expressed on 80% of all CD4
+
  T cells 
and is a co-stimulatory signal for further activation of T cells (Blair et al. 1997).  CD28 is 
comprised of disulfide-linked homodimeric glycoproteins, although some studies have 
demonstrated the ability of CD28 to function in its monomer form as well (Bour-Jordan 
and Blueston 2002). CD28 binds to the B7 protein expressed on the surface of activated 
B cells, monocytes and T cells (Lenschow, Walunas and Bluestone 1996).  The CD28/B7 
pathway plays a major role in T cell activation, especially when activated by low Ag 
concentrations or weak Ag as binding of the TCR/CD3 complex to a specific 
peptide/MHC complex lowers the activation threshold required for T cell activation 
(Bour-Jordan and Blueston 2002). Activation by CD3 alone requires the cross linking of 
approximately 8000 TCRs, as opposed to activation by CD3/CD28, which requires the 
cross-linking of approximately 1000 TCRs (Blair et al. 1997).  The CD28/B7 co-
stimulatory signaling pathway plays other important roles in T cell activation, such as 
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stabilization of IL-2 mRNA (critical for T cell growth), increased expression of Bcl-XL 
(an anti-apoptotic protein that promotes cell survival), and in the early development and 
differentiation of Th1 and Th2 cells  (Bour-Jordan and Blueston 2002; Lenschow et al. 
1996).   
 
B Cells and Their Role in the Immune Response 
 B cells and T cells fall in the class of immune cells known as lymphocytes which 
are the principal cell types involved in the adaptive immune response. B cells make up 
approximately 10% of the immune cell population, and can be identified by cell surface 
expression of the CD19 marker (Goldsby, Kindt, Osborne and Kirby 2003). The primary 
function of B cells is the production of antibodies (Ab) which are Ag-specific 
immunoglobulins whose role is to immobilize and target foreign, pathogenic entities for 
destruction (Bowers 2006a). Unlike T cells, which only recognize Ag presented by an 
MHC molecule, B cells are able to recognize soluble Ag in its cognate native form 
(Chaplin 2006) and are a type of APC whose principal function is to activate immune 
cells against a specific Ag and mount an Ag-specific immune response (Alam 1998).  
 There are two ways in which B cells can be activated to produce Ab, the first type 
is T cell-independent and occurs when the B cell receptor (BCR) recognizes and binds to 
either soluble Ag circulating in the blood or bound Ag presented in the context of an 
MHC molecule on immune cells (e.g. macrophages/monocytes), and the second type is T 
cell dependent and occurs when a B cell recognizes and binds to a TH cell (specifically a 
Th2 cell) previously activated or ―primed‖ by Ag (Goldsby et al. 2003). The result of B 
cell activation is rapid proliferation of B cells, increased Ab production against the 
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specific Ag, and cytokine induction in order to further stimulate other B cells and  
activate other immune cells (Beilhack and Rockson 2003). 
 
Natural Killer (NK) Cells and Their Role in the Immune Response 
 Natural killer (NK) cells are large, granular, cytotoxic lymphocytes capable of 
detecting and eliminating a wide range of tumor cells and, to some extent, virally infected 
cells (Parham 2005). NK cells make up 2% of the immune cell population (5-10% of 
all lymphocytes), and play a critical role in the innate immune response (Alam 1998). NK 
cells express several cell surface markers (CD16, CD56, Fc receptors, etc.) integral for 
proper NK cell functioning which involves the release of cytotoxic molecules called 
perforin and granzyme (a type of protease).  In response to encounter with a virally-
infected or cancer cell, NK cells release these cytotoxic molecules and perforin proteins 
form pore-like structures in the membrane of the target cell. Granzymes and associated 
molecules are then able to enter and induce cell death by both apoptotic and necrotic 
processes (Caligiuri 2008). The mechanisms by which NK cells identify potential target 
cells involve the ability of NK cells to recognize cellular abnormalities, specifically a 
reduction in MHC I surface expression (seen in many cancer and virally-infected cells), 
and the Fc region of specific Ab directed against tumor and viral Ag found on the surface 
of aberrant target cells (called cell-mediated cytotoxicity) (Middleton, Curran and 
Maxwell 2002). In addition to direct destruction of mutated cells by granzymes and 
perforin, activated NK cells secrete cytokines (e.g. IFN- and TNF-α) involved in 
activating other types of immune cells (Le Page, Genin, Baines and Hiscott 2000).  
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Monocytes and Their Role in the Immune Response 
 Monocytes are mononuclear cells responsible for the non-Ag specific recognition 
and elimination of foreign, potentially pathogenic entities (e.g. bacteria, large particulate 
matter, cellular debris, etc.) by a highly metabolic process known as phagocytosis 
(Dobrovolskaia and McNeil 2007), and play an important role in the innate immune 
defense, inflammation and tissue remodeling (Volk, Reinke and Docke 1999). 
Phagocytosis results in the containment and destruction of pathogenic entities by 
enzymatic digestion and ROS production, and subsequent Ag-presentation is critical for 
immune cell activation (Dobrovolskaia and McNeil 2007). Monocytes make up 3-8% of 
circulating leukocytes and two main subsets of monocytes have been identified based on 
differences in phenotype and function (Uthaisangsook et al. 2002). Classical monocytes 
are characterized by high levels of CD14 surface expression (called CD14
++
), and release 
specific cytokines (e.g. IFN-α, TNF-α, IL-1, IL-6, etc.) in response to encounter with Ag. 
These cytokines serve to activate other immune cells and initiate differentiation of 
CD14
++
 monocytes into pro-inflammatory CD14
+
CD16
+
 monocytes (Le Page et al. 
2000). CD14
+
CD16
+
 non-classical monocytes (derived from CD14
++
 monocytes) are 
specifically associated with inflammation, exhibit increased TNF-α secretion, and upon 
stimulation and activation, rapidly proliferate and migrate from the blood to the site of 
assault where they differentiate into tissue-specific macrophages and DC for engulfment 
of foreign material (Mayer 2006; Ziegler-Heitbrock 2007). Phagocytosis is initiated by 
both receptor-and non-receptor mediated processes, the former involving recognition of 
pathogens via specific cell surface receptors such as mannose-receptors, scavenger-
receptors and Fc receptors. Mannose receptors allow for recognition and phagocytosis of 
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bacteria by binding terminal mannose and fucose residues of glycoproteins and 
glycolipids present in microbial cell walls, a feature that distinguishes bacteria from 
mammalian cells whose glycoproteins and glycolipids contain terminal sialic acid or N-
acetylgalactosamine residues instead of mannose and fucose (Kantari, Pederzoli-Ribeil 
and Witko-Sarsat 2008). Similar to mannose-receptors, scavenger-receptors are able to 
detect various microbes as well as low-density lipoprotein (LDL) particles. Monocytes 
also recognize pathogens via Fc receptors which bind the Fc region of Ab attached to 
infected cells and microorganisms (called opsonization) to stimulate phagocytosis in a 
process known as Ab-dependent phagocytosis (Kantari et al. 2008). In addition to Ag 
processing and presentation for immune cell activation, monocytes are capable of 
producing high levels of reactive oxygen species (ROS) for intracellular destruction of 
engulfed pathogenic material located within phagosomes. Fusion of phagosomes with 
digestive enzyme containing lysosomes initiates assemblage of NADPH oxidase subunits 
which catalyze the synthesis of superoxide anion (O2
-
) in a process called the respiratory 
burst. Conversion of O2
-  
to hydrogen peroxide (H2O2) by superoxide dismutase (SOD) 
results in pathogen killing and the importance of this mechanism is illustrated in a genetic 
condition known as chronic granulomatous disease (CGD), a genetic condition in which 
the gene encoding NADPH oxidase is defective or missing, resulting in chronic bacterial 
infections (Ziegler-Heitbrock 2007).  
 
Inflammation and Immune System Activation 
 Inflammation is the complex sequence of biological events due to tissue damage 
caused by a wound, invading pathogens, or other foreign material and is characterized by 
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redness, heat, swelling and pain (Martin and Leibovich 2005). The symptoms associated 
with inflammation are due to three major inflammatory responses, vasodilation, increased 
capillary permeability, and influx of phagocytes (Martin and Leibovich 2005). These 
responses, which are initiated by a complex series of events involving the secretion of 
various cytokines and chemokines, have evolved to allow expedient immune cell access 
to the area of infection for intended clearance of the pathogen (Mackay 2001).   
 Cytokines are soluble low molecular weight signaling molecules (proteins, 
peptides or glycoproteins) secreted by cells for the purposes of cell-to-cell 
communication and immune system regulation (Bellanti, Kadlec and Escobar-Gutierrez 
1994). Although not strictly confined to the immune system, cytokines are essential to the 
development and modulation of both the innate and adaptive immune responses. For 
example, in response to encountering a pathogen, cells of the innate immune system 
secrete specific cytokines which act to activate and recruit other immune cells to help 
fight the foreign pathogen (Mulloy and Rider 2006). Once secreted from a cell, cytokines 
bind to specific cell-surface receptors located on adjacent cells (paracrine), cells in a 
distant location (endocrine), or even the secreting cell itself (autocrine) (Mackay 2001). 
Binding of a cytokine to its ligand produces intracellular cell-signaling cascades which 
result in the up- or down-regulation of genes, transcription factors, and release or 
inhibition of other cytokines and/or cytokine receptors (Mulloy and Rider 2006). The 
effects produced by a particular cytokine depends on many factors, such as cell type, 
cytokine concentration, the absence of specific receptors for that particular cytokine and 
the downstream signaling events that occur due to receptor binding (Alfano and Poli 
2005).  
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 Cytokines play an integral role in inflammation and stimulating immune cell 
activation to fight infection. Although the inflammatory response is designed as a 
protective measure against exposure to foreign, potentially disease causing entities, 
unresolved inflammation (often due to exposure to innocuous substances) can have 
serious and often fatal consequences and is an important consideration when designing 
new therapeutic treatments (Uthaisangsook et al. 2002). Manipulating the inflammatory 
response so that immune cell activation against a specific entity is achieved, is one way in 
which more targeted therapeutic treatments for disease may be accomplished. In 
summary, cytokines are critical in directing and coordinating the immune response and 
three important immunomodulating cytokines described in this research are IFN-, TNF-
α and IL-12. 
 
IFN- 
 Interferon- (IFN- , originally called ―macrophage-activating factor‖) is an acid-
labile, soluble cytokine that is biologically active in its dimerized form, with each 
monomer being comprised of six α-helices (Schroder, Hertzog, Ravasi and Hume 2004). 
IFN- is secreted by NK cells, CD4+ TH cells (specifically Th1 cells), CD8
+
 TC cells and 
DC and has anti-viral, immunoregulatory and anti-tumor properties (Schroder et al. 
2004). IFN-  binds to receptors found on the surfaces of almost all cells of the body 
(with receptor number varying by cell type) to produce a variety of different 
physiological and cellular responses which include, but are not limited to, activating 
macrophages and monocytes to increase Ag presentation and lysozyme activity, 
suppression of the Th2 response and promotion of Th1 response, increases in MHC I 
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expression, promotion of leukocyte migration by increasing adhesion and binding, 
activation of NK cells, and up regulation of various transcription factors involved in 
immunomodulation (Tau et al. 2000).  
 
TNF-α 
 Tumor necrosis factor-α (TNF-α) is a trimeric, 17 kilo-Dalton (kd) (it is 17 kD in 
its secreted form, and 27 kD in its transmembrane noncleaved form) inflammatory 
cytokine with pleiotrophic effects (Wajant, Pfizenmaier and Scheurich 2003). For 
example, the effects of TNF-α can be both growth stimulatory, as seen in the case of 
neutrophil stimulation during inflammation, and growth inhibitory, as seen in neutrophil 
apoptosis upon TNF- α binding to the TNF-R55 receptor (Gaur and Aggarwal 2003). 
TNF-α is produced and secreted by a variety of different cell types including neutrophils, 
T cells, NK cells, and macrophages/monocytes, and receptors for TNF-α are found on 
most cells of the body (Wajant et al. 2003). TNF-α is involved in many different 
biological processes including maintenance of circadian rhythms, replacement and 
remodeling of injured tissues via fibroblast stimulation, fighting pathogenic infections, 
and inducing cell death of cancer-causing cells (Locksley, Killeen and Lenardo 2001). 
However, over-abundant and chronic exposure to TNF-α has been shown to have 
detrimental effects for host health such as pernicious vascular permeability (as seen in  
septic shock), over-activation of immune cells leading to pathologic clot formation, and 
has been shown to play an important role in carcinogenesis (Mocellin and Nitti 2008).  
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IL-12 
 Interleukin 12 (IL-12 is a heterodimeric, cytokine composed of four alpha helices 
and encoded by two separate genes, IL-12A (p35) and IL-12B (p40) secreted primarily 
by B cells, DC, macrophages/monocytes and to a lesser extent, T cells (Maranda and 
Robak 1998). IL-12 is involved in a variety of different functions including stimulation of 
T cell differentiation (Th1) and proliferation, IFN- and TNF-α induction by T cells and 
NK cells, and reduction of IL-4 mediated suppression of IFN- (Goriely and Goldman 
2007). Additionally, IL-12 has clinical relevancy and is being investigated as a potential 
adjuvant for IL-2 adoptive lymphokine-activated killer cell (LAK cell) immunotherapy as 
it reduces the doses of IL-2 required and thus decreases toxicity associated with IL-2 
treatment (Lissoni, Pittalis, Roselli, Rovelli and Vigano 1996).    
Although too much inflammation can be detrimental to the integrity of an 
organism, some inflammation can be beneficial in stimulating an immune response 
against disease causing cells. For example, inflammation stimulates immune cells such as 
monocytes, neutrophils, etc., to produce ROS which induces cytotoxicity in pathogens or 
infected cells and results in robust immune responses against invading entities 
(Uthaisangsook et al. 2002).   
 
Reactive Oxygen Species (ROS) 
 Reactive oxygen species (ROS) are molecules and ions containing unpaired 
valence shell electrons and constitute a type of free radical specifically involving oxygen 
(Bergamini, Gambetti, Dondi and Cervellati 2004). The unpaired valence shell electrons 
make ROS highly reactive, and although ROS play an important role in cell signaling, 
31 
 
excess ROS (called oxidative stress) can result in significant cellular damage which can 
ultimately lead to cellular demise by both necrotic and apoptotic processes (Davies 
2000). Types of ROS formed as a result of the sequential reduction of molecular oxygen 
include superoxide radical (∙O2
-
)superoxide anion (O2
-
), hydrogen peroxide (H2O2) and 
the hydroxyl radical (OH) (Bergamini et al. 2004).   
 Sources of ROS are both exogenous and endogenous in nature. Exogenous 
mediators of intracellular ROS production such as UV light and ionizing radiation exert 
their deleterious effects by damaging DNA, proteins and lipids resulting in cell damage, 
cell death and in some instances the creation of malignant cells (if genes responsible for 
controlling cell growth and replication are damaged). Although excessive ROS 
production can result in cell damage and death, ROS play a critical role in many normal 
cellular functions. For example, ROS can be formed as a necessary intermediate in 
various enzyme reactions and WBC (e.g. neutrophils, macrophages/monocytes, etc.) 
utilization of ROS for host defense mechanisms and cellular communication (e.g. nitric 
oxide) (Valko, Leibfritz, Moncol, Cronin, Mazur and Telser 2007). 
 A major endogenous source of ROS are mitochondria, which produce H2O2 from 
∙O2
-
 as a natural by-product of ATP production as oxygen is reduced along the electron 
transport chain (Bergamini et al. 2004). This can damage cells both directly and 
indirectly as H2O2 interacts with Fe
2+
 or other catalytic metals (a process known as the 
Fenton reaction) and is converted into the highly destructive OH radical (Bacic, 
Spasojevic, Secerov and Mojovic 2008). The metabolism and detoxification of drugs, 
pollutants and ingested particular matter (collectively called xenobiotics) can also serve 
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as a major endogenous source of free radicals which is important to consider when new 
drugs and novel materials are being evaluated for utilization (Valko et al. 2007). 
 Cellular processes, in the form of intracellular enzymes, have evolved to 
neutralize the potentially harmful effects of ROS produced in physiologically moderate 
amounts. These enzymes include superoxide dismutase, catalase, and the glutathione 
enzymes (e.g. glutathione-peroxidase, glutathione-reductase and S-glutathione 
transferase) (Willcox, Ash and Catignani 2004). Superoxide dismutase is found in both 
the mitochondrial matrix and cytoplasm and catalyzes the formation of H2O2, O2 and 
water from the potent highly damaging superoxide radicals (O2
-
) produced in the 
electron transport chain. Under conditions in which superoxide dismutase becomes 
overwhelmed (e.g. during oxidative stress), excessive amounts of H2O2 are produced 
resulting in the formation of OH
 
via the Fenton reaction (Benzie 2000).  
 Catalase is localized in digestive organelles known as peroxisomes and exerts its 
antioxidant effects by reacting with H2O2 to catalyze the formation of O2 and water 
(Djordjevic 2004). Glutathione is an important antioxidant tri-peptide synthesized from 
the amino acids L- cysteine, L-glutamic acid and glycine, and in its reduced state 
participates in conjugation reactions to remove various toxic metabolites and donates 
electrons to unstable ROS molecules (Devasagayam, Tilak, Boloor, Sane, Ghaskadbi and 
Lele 2004).  
During oxidative stress glutathione precursors become depleted and glutathione 
production is insufficient in neutralizing the ROS generated. To combat diminished 
glutathione levels, exogenous supplemental cysteine rich compounds, such as N-acetyl 
cysteine (NAC) can be used to restore glutathione precursor reserves for conversion by 
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specific enzymes and replenishment of glutathione stores (Townsend, Tew and Tapiero 
2003).   
 Excessive ROS production has been implicated in a variety of different human 
diseases such as cancer, atherosclerosis and neurodegenerative disorders, and exerts its 
damaging effects by reacting with cellular components, causing cell death by both 
necrotic and apoptotic processes.   
 
Cell Death: Apoptosis and Necrosis 
 Cell death can occur by two different mechanisms, apoptosis and necrosis. 
Apoptosis is a type of programmed cell death or ―cell suicide‖ involving a predictable 
series of biochemical events and morphological changes such as decreased cell volume, 
modification of the cytoskeleton resulting in membrane blebbing, chromatin 
condensation and DNA fragmentation (Winoto 1997). Subsequent to these changes, the 
apoptotic cell breaks into small membrane-bound particles called apoptotic bodies which 
signal phagocytic immune cells (e.g. macrophages and monocytes) to engulf the 
apoptotic bodies, avoiding the release of cellular contents into the surrounding tissue and 
induction of a local inflammatory response (Elmore 2007). Unlike apoptosis, necrosis is 
not programmed by the cell, but is cell death due to overwhelming injury from which the 
cell is unable to recover. In necrosis, the damage incurred causes the cell to swell and 
burst, spilling its cellular contents into the surrounding environment and the dispersed 
cellular debris triggers an inflammatory response in an effort to clear the debris and 
remove the offending stimulus (Proskuryakov, Gabai, Konoplyannikov, Zamulaeva and 
Kolesnikova 2005). Apoptosis is essential in maintaining homeostasis and host health and 
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is critical for cell differentiation during embryogenesis. Additionally, apoptosis is 
responsible for sustaining a stable number of cells in the body, controlling the growth of 
aberrant mutated cells and is one of the mechanisms by which immune cells, namely NK 
and TC cells, induce cytotoxicity. Also, the absence of apoptosis (due to genetic 
mutations, for example) can have dire consequences for the organism resulting in the 
development of diseases such as cancer and autoimmunity (Kam and Ferch 2000).  
 
 In conclusion, the utilization of NP (specifically metal oxide NP) is ever-
increasing, and NP are already found in many different commercial products. Due to their 
unique properties, it is essential to elucidate the effects and mechanisms of NP-biological 
interactions and investigate the biomedical potential of different types of particles on 
various cell types and systems. Evaluating parameters influencing NP toxicity ensures the 
safe use of NP for various industrial applications and may allow for the creation of new 
and improved therapeutic treatments for disease. Our immediate goal is to examine the 
differential toxic effects of metal oxide NP, specifically ZnO NP, on primary human 
immune cells. The main hypothesis of this research is that ZnO NP toxicity is dependent 
on various parameters including cell type, NP size, and cell-activation state. Additionally, 
our research evaluated specific mechanisms of toxicity, cell death and the inflammatory 
potential of ZnO NP in immune cells. Exploitation of these observations may enable the 
development of novel treatments for disease, which is the long term goal of our research. 
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EXPERIMENTAL PROCEDURES 
 
Preparation and Characterization of ZnO NP 
ZnO NP utilized in all experiments were synthesized in diethylene glycol (DEG) 
via forced hydrolysis of zinc acetate (Reddy et al. 2007). In brief, zinc acetate was 
dissolved in DEG, and nanopure water was added under magnetic stirring. Subsequently, 
the system was heated at 160 ºC under reflux for 90 min. After cooling, the resulting 
product was removed from DEG via centrifugation and washed with ethanol several 
times before drying for 24 h at 50 °C, resulting in a powder sample. The sample crystal 
phase, crystallite size and morphology were characterized via x-ray diffraction (XRD), 
and transmission electron microscopy (TEM) (Hanley et al. 2008; Reddy et al. 2007). 
The NP powder was weighed and reconstituted in phosphate buffered saline (PBS) 
solution to the desired stock concentration. After reconstitution, NP were sonicated for 10 
min and immediately vortexed prior to addition to cell culture samples. For all 
experiments, except for those directly comparing effects of NP size on cell viability and 
ROS production, 8 or 13 nm ZnO NP were used as specified.  
Different sized ZnO NP were synthesized as described above and sizes altered by 
modifying the hydrolysis molar ratio of water to zinc acetate with ratios of  2.4, 6.1, 12.2, 
and 36.6 yielding NP with  average diameters of  4 nm, 8 nm, 13 nm, and 20 nm, 
respectively. The corresponding particle size for all four NP sizes analyzed reveals a 
narrow size distribution and XRD patterns indicate all of the ZnO samples are well 
indexed to pure wurtzite crystallite phase of ZnO. Furthermore, the average crystallite 
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sizes estimated using the peak widths (full width at half maximum) of the XRD patterns 
agree well with TEM results.  
 
Preparation of FITC-Doped ZnO NP 
 FITC encapsulated ZnO (FITC-ZnO) particles were synthesized by forced 
hydrolysis and condensation of FITC-binding silane and silicate to obtain the FITC-SiO2 
core (Burns, Ow and Weisner 2006), and the ZnO surface layer formed using zinc salt 
(Wang et al. 2009). The core-shell structure of the ~200 nm sized FITC-ZnO particles 
and the presence of a surface layer of 13 nm sized ZnO NP were confirmed using TEM, 
XRD and x-ray photoelectron spectroscopy (XPS) studies, and fluorescence properties 
were investigated using photoluminescence spectroscopy and flow cytometry (Wang et 
al. 2009).  
 
Preparation of SnO2 and CeO2 NP 
 SnO2 NP were synthesized by our collaborators using methodologies nearly 
identical to those described for ZnO NP preparation (Reddy et al. 2007). Briefly,  SnO2 
NP were synthesized in diethylene glycol (DEG) via forced hydrolysis of tin chloride and 
the resulting product was removed from DEG via centrifugation and washed with ethanol 
several times before drying for 24 h at 50 °C, resulting in a powder sample of 4-8 nm 
sized NP. CeO2 NP were synthesized from cerium nitrate by sol-gel preparation resulting 
in a 9 nm NP powder sample. For use in mammalian cell cultures, NP were weighed 
and reconstituted in phosphate buffered saline (PBS) solution to the desired stock 
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concentration, sonicated for 10 min, and immediately vortexed prior to addition to cell 
samples.  
 
Immune Cell Isolation and Cell Culture 
Isolation of Peripheral Blood Mononuclear Cells (PBMC)  
 For isolation of PBMC (peripheral blood mononuclear cells) and immune cell 
subsets, written informed consent was obtained from all blood donors and the University 
Institutional Review Board approved this study. PBMC were obtained via Ficoll-
Hypaque (Histopaque-1077, Sigma, St Louis, MO) gradient centrifugation using 
heparinized phlebotomy samples (Coligan 1995). After removal of the leukocyte layer, 
cells were washed three times with Hank’s buffer (Sigma, St. Louis, MO) and 
resuspended to a final concentration of 1-2 x 10
6
 cells/mL in RPMI-1640 (Sigma) 
containing 10% fetal bovine serum (FBS) and cultured at 37 C and 5% CO2. 
 
Primary CD4
+
 T Cell Isolation  
 After isolation of human PBMC, CD4
+
 T cells were purified using negative 
immunomagnetic selection per manufacturer’s instructions using a cocktail of antibodies 
against CD8, CD14, CD16, CD19, CD56, and glycophorin A (StemCell Technologies, 
Vancouver, BC) with collection of unlabeled T cells (typically >97% CD4
+ 
 and >90% 
viable as assessed by flow cytometry).
 
Purified CD4
+
 cells were cultured in RPMI/10% 
FBS and suspended at a final concentration of 1-2 x 10
6
 cells/mL. 
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Primary CD14
+
 Monocyte Isolation  
 PBMCs were obtained by Ficoll-Hypaque density centrifugation as described 
above and CD14
+ 
cells isolated from the mixed cell suspension. Negative 
immunomagnetic selection was performed according to the manufacturer’s protocol 
using a cocktail of antibodies directed against CD2, CD3, CD16, CD19, CD20, CD56, 
CD66b, CD123, glycophorin A (StemCell Technologies, Vancouver, BC). For optimal 
cell recovery, PBMCs were first blocked with anti-human CD32 (Fc RII) blocker 
reagent before labeling with the antibody cocktail and running through the column. 
Collection of CD14
+
 monocytes was typically >97% viable as assessed by flow 
cytometry. Purified monocytes were then cultured in RPMI/10% FBS at 5 x 10
5
 cells/mL 
in 200 L total volume in 96-well microtiter plates at 37 C and 5% CO2. 
 
Jurkat Lymphoma, Hut-78 Leukemic, and U937 Monocytic Cancer Cell Lines 
 The Jurkat lymphoma T cell, Hut-78 leukemic T cell and U937 monocytic cancer 
cell lines  (ATTC, Rockville, MD) were cultured in RPMI 1640 supplemented with 10% 
FBS (Jurkat) or 20% FBS (U937) and 2 mM L-glutamine, 1.5g/L sodium bicarbonate, 
4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate. Cells were maintained in 
log phase at 37 C and 5% CO2 and seeded at 5 x 10
5
 cells/well in 96-well plates for 
individual experiments. 
 
Antibodies (Ab) and Flow Cytometry 
 Flow cytometric analyses were performed using a 4-color Epics XL flow 
cytometer (Beckman Coulter, Fullerton, CA). Immunofluorescent staining was 
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accomplished by harvesting cells plated at a concentration of 1 x 10
6
 cells/mL into FACS 
buffer and centrifuging for 10 min at 2000 rpm to pellet cells. After supernatant removal, 
cells were resuspended in FACS buffer and stained with fluorescently labeled Ab 
(Beckman Coulter, Fullerton, CA). Appropriate concentrations of each Ab were 
determined by titration for optimal staining prior to experimental use. Cells were 
incubated with the appropriate fluorescent Ab for 30 min at 4C, washed two times, 
harvested into FACS buffer and immediately analyzed. Ten thousand events gated on the 
parameters of size (forward scatter - FS) and granularity (side scatter - SSC) were 
analyzed, and expression of the percentage of positively staining cells or the mean 
fluorescence intensity (MFI) determined by comparisons to isotype controls. In PBMC 
cultures, individual cell types were distinguished from one another based on differential 
Ab staining and FS and SSC properties.  T cells were defined as CD3
+
; TH defined as 
CD3
+
,CD4
+
; naïve T cells defined as CD3
+
,CD45RA
+
; memory T cells defined as CD3
+
, 
CD45RO; B cells defined as CD19
+
,CD3
-
;  NK cells defined as CD56
+
,CD16
+
, CD3
-
,  or 
CD56
+
, CD3
-
; and monocytes defined as CD14
+
,CD3
-
.  To prevent indiscriminate Ab 
staining of monocytes via Fc receptors, 100 L of heat-inactivated human AB serum was 
added to experimental samples immediately prior to staining. 
 
T Cell Activation and Culture Conditions 
 Purified CD4
+
 cells were cultured in RPMI/10% FCS at 1 x 10
6
 cells/mL in 200 
μL total volume and activated using immobilized CD3 Ab (1.0 g/well of clone OKT3, 
ATCC, Rockville, MD) +/- CD28 Ab (0.25 g/well of clone CD28.2 (PharMingen, San 
Diego, CA) in 96-well tissue culture plates. Cultures were treated with freshly prepared 
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and sonicated NP, or left untreated for varying lengths of time and analyzed using flow 
cytometry and a microplate reader. T cell activation was verified by detecting an increase 
in membrane CD40L protein expression using flow cytometry.  
 
Cell Viability Assays 
Flow Cytometric Analysis of Immune Cell Viability 
To assess the effect of ZnO NP on PBMC and isolated immune cell viability, two 
different flow cytometric assays were employed. In the first assay, cells identified were 
stained and identified using fluorescently labeled Ab and viability determined by staining 
with 50 g/mL of propidium iodide (PI), a fluorogenic dye used to monitor losses in cell 
membrane integrity, for 10 min prior to analysis. Fluorescent CountBright
® 
counting 
beads (Invitrogen, Carlsbad, CA) were added to samples to enable determinations of 
absolute cell numbers, and flow cytometry used to evaluate changes in PI staining and 
quantify cell death.  NP were excluded from the analysis based on absence of 
fluorescence signal and light forward scatter (FS) and side scatter (SSC) characteristics. 
In experiments testing the effects of micron-sized bulk ZnO on cell viability, purified 
CD4
+
 T cells were left untreated or treated with various concentrations of commercially 
available (Sigma Aldrich, St. Louis, MO) bulk ZnO powder or laboratory synthesized 
ZnO NP resuspended in PBS, cultured for 20-24 h, and viability assessed using PI and 
analyzed by flow cytometry. Identical conditions to those just described were used for 
experiments testing the effects of SnO2 NP and CeO2 NP on T cell viability, except that 
only one concentration (e.g. 10 mM) of either SnO2 NP or CeO2 NP was evaluated.  
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A second viability assay, the LIVE/DEAD viability assay for mammalian cells 
(Invitrogen, Eugene, OR) was used to verify results seen using PI. Per manufacturer’s 
protocol for flow cytometry, purified CD4
+
 T cells were dually stained with two 
fluorescently labeled probes that enable the simultaneous determination of live and dead 
cells in a sample. Calcein AM was used to stain live cells as it fluoresces only when 
cleaved by intracellular esterases, and EthD-1 was used to identify dead/dying cells as it 
exclusively enters cells with disrupted cell membranes. 
 
Flow Cytometric Analysis of Bacterial Viability 
 Two different strains of bacteria (E. coli and S. aureus) were provided by our 
collaborator, Dr. Kevin Feris, for determination of bacterial cell viability. Bacterial 
cultures (E.coli and S. aureus) were grown for 3 h in LB medium and subsequently 
treated with ZnO NP resuspended in PBS. After 15 h of treatment, a two color live/dead 
BacLight
®
 bacterial viability kit (Molecular Probes, Carlsbad, CA) was used to determine 
cell viability as analyzed by flow cytometry. The ratio of dead to live bacteria remaining 
in the culture following NP exposure was determined by simultaneously staining with PI 
and a green fluorescent dye, Syto9, that intensely stains cells with intact membranes and, 
to a lesser extent, cells with damaged membranes. Populations of live (green) and dead 
(red) bacteria were discriminated based on green and red fluorescence staining profiles 
and changes in FS and SSC characteristics. 
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Alamar Blue Viability Assay 
 The Alamar Blue viability assay, which utilizes the fluorogenic redox indicator 
dye, Alamar Blue, was also used to evaluate NP-induced cytotoxicity. This dye becomes 
fluorescent upon reduction by mitochondrial enzymes in metabolically active (live) cells. 
Cells were seeded into 96-well plates at 5 x 10
5
 cells/mL in a final volume of 200 L and 
treated with ZnO NP for 18 h. Alamar Blue (20 L) was added to cultures for an 
additional 6 h of culture for a total NP-exposure time of 24 h. A BioTek
®
 
spectrophotometer was used with an excitation/emission at 530/590 nm to monitor and 
record changes in fluorescence and viability was normalized to fluorescence values from 
control wells.  
 
Determination of IC50 Values for Immune Cells 
 To determine the concentration at which 50% of cells remain viable (IC50), 
experiments were performed testing the effects of varying concentrations of ZnO NP on 
cell viability. To determine the IC50 values for purified T cell and monocytes, cells were 
treated with varying concentrations of ZnO NP (1 mM, 5 mM and 10 mM for T cells and 
0.0625 mM, 0.25 mM, 0.5 mM and 1 mM for monocytes) for 22-24 h and viability 
assessed using the Alamar Blue assay. The program GraphPad Prism

 5.0 was used to 
calculate IC50 values for purified CD4
+ 
T cells and CD14
+
 monocytes by plotting cell 
viabilities against the logarithm of NP concentration and using a nonlinear regression 
analysis to fit a variable slope dose-response curve. For cells found in mixed PBMC 
cultures, cell types were identified using fluorescently labeled antibodies against specific 
plasma membrane markers and viabilities determined by PI uptake and flow cytometry. 
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To calculate IC50 values for these flow cytometric experiments, cell viabilities were 
plotted against NP concentrations and a linear regression analysis used to determine IC50 
values. 
 
Reactive Oxygen Species (ROS) Assays 
ROS Detection 
 To assay for NP-induced ROS production in primary lymphocytes and 
monocytes, cultures of mixed PBMC were obtained from whole blood treated with an 
ammonium chloride lysing solution (1.5 M NH4Cl, 0.1 M NaHCO3, 0.01 EDTA) used to 
lyse red blood cells and centrifuged for 10 min at 4C to remove erythrocytic debris. 
PBMC were counted, resuspended in phenol red-free RPMI to a final concentration of 1 
x 10
6
 cells/mL and treated with 1 mM or 5 mM of ZnO NP (8 nm). To evaluate ROS 
production, cells were loaded with 5 M of the oxidation-sensitive dye, 2’,7’-
dichlorofluorescein diacetate (DCFH-DA, Invitrogen, Carlsbad, CA) for 20 min prior to 
analysis. The oxidation product of DCFH-DA has an excitation/emission maxima of 
~495 nm/529, enabling detection both by using a microplate reader and flow cytometry 
(Luo et al. 2002). In flow cytometric analyses, CD3
+
 lymphocytes and CD14
+
 monocytes 
were identified based on FS and SSC gating and staining with fluorescently labeled Ab, 
allowing for simultaneous cell identification and evaluation of ROS production. 
Additionally, ROS production in PBMC cultures was measured after several different 
NP-exposure times (6 h – 24 h) to assess the kinetics of NP-induced oxidative stress. To 
compare NP-induced ROS in primary cells with cancer cells, Hut-78 T leukemic cells 
were treated with ZnO NP and ROS measured using similar methodology as described 
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for primary cells. As a positive control for ROS production in all cell types tested, 
untreated (no NP) cells were loaded with DCFH-DA and activated with PMA (25 ng/mL) 
for 1 h prior to analysis. 
In parallel experiments investigating the effect of NP size on ROS production, 
bulk cultures of PBMC were treated with various concentrations (5 mM and 10 mM) of 
different sized ZnO NP (4, 13, and 20 nm), loaded with DCFH-DA and ROS production 
analyzed using a fluorescent microplate reader as described by others (Hong and Liu 
2004; Onaran, Sencan, Demirtas, Aydemir, Ulutin and Okutan 2008).  
 
ROS Quenchers 
 To determine the role of ROS in NP-induced cell death, primary purified CD4
+
 T 
cells and CD14
+
 monocytes were seeded in a 96-well plates at a concentration of 5 x 10
5
 
cells/mL and treated with the ROS scavenger, N-acetyl cysteine (NAC, Sigma Aldrich, 
St. Louis, MO). NAC was made as a stock solution in sterile nanopure water and added 
to cells at a final concentration of 5 mM. Cells were pretreated with NAC for 2 h to allow 
time for NAC to enter the cells before treating with various concentrations of 8 nm ZnO 
NP for 24 h. Viability was determined using the Alamar Blue cytotoxicity assay and a 
fluorescent microplate reader.  
 
Confocal Microscopy 
Apoptosis Versus Necrosis 
 Mechanisms of ZnO NP-induced cytotoxicity were evaluated by confocal 
microscopy using two different fluorescent staining techniques; acridine orange and 
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Vybrant® Apoptosis Assay Kit #2- AlexaFluor® annexinV/propidium iodide by 
Invitrogen (Eugene, OR). Acridine orange stains double stranded DNA and allows for 
visualization of nuclear morphology. Invitrogen’s Vybrant annexin V assay makes use of 
two different fluorescently labeled probes, annexin V and PI, to differentiate between 
live, necrotic and apoptotic cells. Briefly, Jurkat T cells were suspended in complete 
RPMI-1640 medium and plated at 5 × 10
5
 on poly-D lysine coated glass bottom culture 
dishes (P35GC-1.5 mm-14 mm-C) supplied by MatTek Corporation (Ashland, MA). 
Samples were left untreated, treated with 0.3 mM ZnO NP, or with 100 nM okadaic acid 
as a positive control for apoptosis. Following a 20 h incubation at 37 C (5% CO2), cells 
were washed and stained with annexin V Ab/PI per manufacturer’s protocol or stained 
with 5 μg/ mL acridine orange (AO) for 10 min at 37 C, followed by washing and 
resuspension in PBS. Cells were visualized using a Zeiss LSM 510 META laser scanning 
confocal microscope (Zeiss, Germany). Images were acquired using factory-set 
dichronics (an argon laser set and two helium neon lasers) with either 63 × Plan 
Apochromat 1.4 oil DIC or 100× Plan Fluar 14.5 oil objective. Image acquisition and 
processing was performed using the LSM 510 META software. 
 
NP Association with Immune Cells 
 NP-cell interactions were investigated using both flow cytometric analysis and 
visualization using confocal microscopy. Bulk cultures of PBMC were left untreated or 
treated with 5 mM FITC-doped ZnO NP for 16 h and cell types identified by staining 
with fluorescently labeled Ab. Cell identification and FITC-NP/cell associations were 
assessed using flow cytometry and both the percentage of fluorescent cells (FACS%) and 
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mean fluorescence intensity (MFI) values for CD3
+
 T cells, CD4
+
 TH cells, CD19
+
 B cells 
and CD14
+
 monocytes determined.    
 To examine NP intracellular localization versus extracellular plasma membrane 
association, confocal microscopy was used to calculate the average number of FITC-
doped NP/z-series slice in both Jurkat T and monocytic U937 cells. Cells were suspended 
in RPMI-1640 medium and plated  at 5 x 10
5
 cells/mL on poly-L lysine coated glass-
bottom culture dishes (P35GC-1.5 mm-14 mM-C) supplied by MatTek Corporation 
(Ashland, MA) for a 24 h to allow cellular adherence to plates.  Jurkat T cell lymphoma 
cells were left untreated and treated with 0.5 mM FITC-doped ZnO NP  for 8 h at 37 C 
(5% CO2). Cells from the monocytic cancer U937 cell line were left untreated and treated 
with 0.3 mM FITC-doped ZnO for 20 h using identical parameters as above. Following 
incubation, cells were washed with PBS and stained with fluorescent Ab for cell 
identification; fluorescent anti-CD14 PE for U937 and fluorescent anti-CD3 for Jurkat. 
After staining, cells were washed twice with PBS to remove excess Ab and reduce 
fluorescent background signal before being visualized using a Zeiss LSM 510 META 
laser scanning confocal microscope (Zeiss, Germany). Images were acquired using 
factory-set dichronics (an argon laser set and two helium neon lasers) with either 63x 
Plan Apochromat 1.4 oil DIC or 100x Plan Fluar 14.5 oil objective. Image acquisition 
and processing was performed using LSM 51- META software. FITC-doped ZnO NP 
were counted in multiple images for each cell type by examining individual slices from a 
Z-series image.  Orthogonal viewing was performed to verify intracellular localization of 
NP compared to extracellular membrane association. 
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Enzyme-Linked Immunosorbent Assay (ELISA) 
 To investigate the effect of ZnO NP treatment on cytokine production, a sandwich 
enzyme linked immunosorbent assay (ELISA) was employed to allow for detection and 
quantification of soluble cytokine released into culture medium. Human IFN-, TNF-α 
and IL-12 were measured in primary peripheral blood mononuclear (PBMC) cells at a 
concentration of 1 x 10
6
 cells/mL. PBMC were left unactivated or activated with 1000 
U/mL of IFN- (Peprotech, Rocky Hill, NJ) for 14 h and subsequently treated with 
varying concentrations of 8 nm ZnO NP (0.05 mM, 0.1 mM and 0.2 mM) for 24 h. 
Control (no activation and no NP treatment) samples were also included to allow for 
background cytokine expression. Following incubation, cell-free supernatant was 
harvested via successive 10 min centrifugations (2,000 rpm, 7,000 rpm and 13,000 rpm) 
and cell supernatants stored at -80 C until analysis. ELISA was performed by the 
UMAB Cytokine Core Laboratory (Baltimore, MD), with all samples analyzed in 
triplicate and cytokine production expressed in pg/mL. IL-12 expression was measured in 
PBMC left unactivated or activated with IFN- (1000 U/mL) both alone and in the 
presence of ZnO NP. Expression of IFN- and TNF-α was assessed as described above 
except that exogenous IFN- was not added to cell culture samples.  
 
Data Analysis 
All data was analyzed using SAS, Inc. software (Cary, NC). Data for Figures 2, 4, 
5, 6, 7, 8, and 10 were analyzed using repeated measures analysis of variance (ANOVA) 
with post hoc comparisons and significance levels defined as p < 0.05. Repeated 
measures of variance analyses were used when two or more measurements of the same 
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type were made on the same subject to determine statistical differences between the 
means and to allow separation of within-subject variation from between subject variation. 
Data for Figures 12, 13, and 18 were analyzed using a two-way analysis of variance 
(ANOVA) to test for overall statistical significance of the model and post hoc 
comparisons were used to test for statistically significant effects of treatment on cell 
viability (p< 0.05). 
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RESULTS 
 
ZnO NP Display Cytotoxic Effects in T Cells Compared to Bulk ZnO 
To determine if reduction of ZnO to the nano-scale alters the biological effects of 
ZnO, we performed experiments comparing the effects of bulk micron-sized ZnO and 
13 nm sized ZnO NP on isolated primary human CD4+ T cell viability. ZnO NP were 
synthesized and characterized by our collaborators in the Punnoose lab by collection of 
ZnO NP powder after separation from DEG medium via centrifugation. In agreement 
with the XRD results (Reddy et al. 2007), transmission electron microscopy (TEM) 
measurements were carried out to further investigate ZnO particle size and shape (Figure 
1A) and average particle size of the NP estimated using the Scherrer relation was found 
to be 13 nm, with a range of particle sizes (7-19 nm) observed (Figure 1B).  
Experiments were performed testing identical concentrations of both ZnO NP and 
bulk ZnO suspended in a phosphate buffered saline (PBS) solution on human CD4
+
 T 
cells. Dual-color flow cytometry was used to simultaneously identify cells and assess cell 
viability using propidium iodide (PI), a red fluorescent nuclear stain that enters only cells 
with disrupted plasma membranes (Figure 2).  No appreciable loss of viability was 
observed in T cells treated with micron-sized bulk ZnO powder at any concentration 
tested, conversely, ZnO NP treatment caused significant decreases in viabilities at 
concentrations  ≥ 5 mM (p=0.0001). This data indicates that T lymphocyte cytotoxicity  
is limited to ZnO in the nanoscale size range, as no significant effect of bulk ZnO powder 
was found at any of the concentrations tested (0.5 – 10 mM).  
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Differential ZnO NP Toxicity to E. coli and S. aureus 
  For bacterial studies performed by our collaborator, Dr. Kevin Feris, ZnO NP and 
bulk ZnO powders were suspended in diethylene glycol (DEG) to desired stock 
concentrations and two different bacterial strains, E. coli and S. aureus, were treated with 
varying concentrations of  13 nm sized ZnO NP. Results from these studies 
demonstrated a differential inhibition of colony forming units (CFU) between the two 
bacterial strains in response to ZnO NP treatment, with S. aureus exhibiting greater CFU 
inhibition at lower concentrations compared to E. coli (Reddy et al. 2007).  
 To confirm ZnO NP definitively kill bacteria as opposed to merely inhibiting their 
growth, we performed experiments in which bacteria were treated with 5 mM NP (E. 
coli) or 2 mM NP (S. aureus) for 15 h and viability was determined using a 2-color 
live/dead BacLight
®
 bacterial viability kit
 
(Invitrogen, Eugene, OR) in which populations 
of live and dead bacteria were discriminated based fluorescence staining profiles. As seen 
in Figure 3, substantial losses in viability were observed in both types of bacteria, with S. 
aureus being the most susceptible (>59% loss of viability) followed by E. coli (>30% 
loss in viability). This data combined with additional bacterial studies contributed by our 
collaborator, Dr. Kevin Feris, and our own T cell viability demonstrate that T cells are 
significantly less susceptible to ZnO NP-induced toxicity compared to both E. coli and S. 
aureus at the same concentrations tested (p=0.000) (Reddy et al. 2007). Collectively, 
these results indicate that ZnO NP toxicity occurs in a cell-dependent manner, with 
significant differences in viability observed among different strains of prokaryotes (S. 
aureus are killed at lower NP concentrations compared to E. coli) and between 
prokaryotes and eukaryotes (T cells are more resistant to NP treatment compared to both 
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strains of bacteria) (Reddy et al. 2007). To expand our understanding of factors affecting 
ZnO NP toxicity, we conducted experiments to investigate the parameters affecting ZnO 
NP toxicity in primary human immune cells.  
 
Preferential Killing of Activated Versus Unactivated T Cells 
To determine if differential toxicity to ZnO NP is dependent upon the 
microenvironment or signaling status of eukaryotic cells, toxicity effects were determined 
in resting primary human T cells and compared to cells activated through the T cell 
receptor (TCR). Signal transduction through the TCR pathway is recognized as an 
essential event required for resting T cells to enter the cell cycle and proliferate (Foell, 
Hewes and Mittler 2007) and a second signal provided by ligation through the CD28 
receptor protein augments TCR signaling and enables maximal T cell activation and 
proliferation. For these studies, normal peripheral blood CD4
+
 T cells were isolated using 
negative immunomagnetic selection and either activated with stimulatory TCR Ab (anti-
CD3), co-stimulated with both CD3 Ab (anti-CD3) and CD28 Ab (anti-CD28), or left 
unactivated. The effects of ZnO NP on plasma membrane damage were assessed using PI 
and flow cytometry. As shown in Figure 4A, the toxicity of ZnO NP to T cells is 
dependent on the activation state of the cell, with resting T cells exhibiting the greatest 
resistance to ZnO NP at all concentrations tested. The unactivated status of these cells 
was verified by their lack of appreciable CD40L protein expression, a sensitive marker of 
T cell activation Figure 4B. Conversely, T cells partially activated by stimulation through 
the TCR pathway alone displayed significantly greater sensitivity to ZnO NP at all 
concentrations (p=0.0007 for control versus CD3 at 1 mM, p=0.0009 at 5 mM and 
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p=0.0052 at 10 mM NP). The partial activation status of these cells was verified by 38% 
± 6.2% of the cells expressing membrane CD40L. Importantly, T cells activated through 
both the TCR and CD28 co-stimulatory pathway showed an even greater sensitivity to 
ZnO NP toxicity (e.g. 55% viability in CD3/CD28 activated versus 69% in CD3 activated 
cells at 1 mM) which significantly differed from CD3 activated cultures at both 1 mM 
(p=0.0044) and 5 mM NP (p=0.0246) concentrations. Staining for membrane CD40L 
expression confirmed a greater extent of T cell activation in CD3/CD28 activated cultures 
(67% ± 7.0% positive staining).  
Control experiments using bulk micron sized ZnO powder or NP-free supernatant 
showed no appreciable toxicity effect at any of the concentrations tested (e.g. viability 
with bulk ZnO: 95 ± 0.5% at 0 mM, 96 ± 3% at 1 mM, 91 ± 3% at 5 mM, 91 ± 1% at 10 
mM; 98% viability with NP-free supernatant equivalent to 1–10 mM). In addition to PI 
uptake associated with disruption of plasma membrane integrity, NP-induced cell death 
following ZnO NP treatment was supported by an increase (17%; MFI change of 48–
56) in light side scatter characteristics indicative of increased cell granularity and a 
concurrent decrease (8%; MFI change of 156–144) in forward scatter reflects a decrease 
in cell size at 10 mM NP concentrations. These results demonstrate significantly greater 
cell death in activated T cells compared to resting cells over a relatively large range of 
NP concentrations tested (1–10 mM), and toxicity varies with the extent of T cell 
activation. 
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Cancerous Cells Are Preferentially Killed by ZnO NP Compared to Normal Cells 
Given that differential ZnO NP toxicity exists between quiescent T cells and those 
activated with specific signals to trigger proliferation, experiments were performed to 
determine whether continuously dividing cancer cells display an even greater sensitivity 
to ZnO NP toxicity. Jurkat leukemic and Hut-78 lymphoma T cell lines were treated with 
ZnO NP for 24 h and viability was determined by PI uptake (viability of cancer cell lines 
was performed by lab member Janet Layne). Results from these experiments demonstrate 
both T cell cancer lines display strikingly greater (28–35 fold) sensitivity to NP toxicity 
compared to resting normal T cells (Figure 5A). Significant differences were observed 
between Hut-78 and normal T cells (p=0.0101 and 0.0434 at 1 mM and 5 mM NP, 
respectively) and Jurkat and normal T cells (<0.0001 at both 1 and 5 mM NP). No 
appreciable loss of primary T cell viability was observed at NP concentrations (e.g. 0.5 
mM) that effectively killed cancer T cells.  
To validate experimental results, similar experiments were performed using the 
LIVE/DEAD
®
 viability assay (Invitrogen, Eugene, OR). This assay allows for the 
simultaneous determination of live and dead cells in a sample by labeling live cells with 
the Calcein AM dye that fluoresces only when cleaved by intracellular esterase enzymes 
and the vital dye, EthD-1, which only enters dead/dying cells with disrupted cell 
membranes. As shown in Figure 5B, nearly identical results were obtained using this 
independent assay for viability, with ZnO NP displaying preferential toxicity against 
cancerous cells compared to normal cells of identical lineage. It should be noted that no 
statistically significant change in primary T cell viability occurs between untreated 
primary control cells and these cells treated with low NP concentrations (0.2 and 0.5 
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mM), while a significant decrease (p<0.0001) in Jurkat leukemia cell viability can readily 
be seen at the lowest concentration tested (52% viable/48% dead at 0.2 mM), with no 
live cancer cells detectable at 5 mM NP.  
 
Memory T Cells Display Greater Sensitivity to ZnO NP-Induced Cytotoxicity 
 The activation of T cells in response to specific Ag results in a cascade of 
intracellular signaling events and differentiation of ―naïve‖ T cells into ―memory‖ cells, 
which can become activated much more readily upon subsequent exposure to the original 
Ag (Surh and Sprent 2008). Given that activation thresholds and alterations in 
intracellular calcium and signaling responses differ between naïve and memory T cells, 
experiments were performed to determine whether memory T cells, display greater 
sensitivity to ZnO NP toxicity compared to naïve T cells. Isolated PBMC were treated 
with 8 nm ZnO NP for 22-24 h and viability assessed by PI uptake and flow cytometry. 
Naïve CD3
+
 T cells were identified based on expression of the CD45RA (CD45RA
+
, 
CD3
+
) surface marker, while memory T cells were defined as CD45RO
+
, CD3
+
. The 
cytotoxic responses of naïve and memory CD3
+
 T cells to ZnO NP were compared to 
bulk cultures of CD3
+
 T cells (containing a mixture of both naïve and memory cells) 
from the same blood donor. As shown in Figure 6,  memory T cells displayed 
significantly greater sensitivity to NP toxicity compared to either naive T cells or bulk 
cultures of CD3
+
 T  cells  (p=0.0044  and p=0.0244) at 10 mM ZnO NP.  Naïve T cells 
appeared more resistant to ZnO NP-induced cytotoxicity compared to total CD3
+
 T cell 
samples, although statistically significant differences were not observed (p=0.08). These 
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results provide further evidence that susceptibility to ZnO NP-induced toxicity may be 
related to the activation threshold and/or proliferation potential of the cell.  
 
Kinetics of ZnO NP-Mediated Toxicity to Normal and Cancerous T Cells 
 To further elucidate differences in normal versus cancerous immune cells, 
experiments were performed to determine and compare the kinetics of ZnO NP toxicity 
in primary versus cancerous T cells. Cells were treated with ZnO NP and concentrations 
chosen for each cell type (10 mM for primary T cells and 0.5 mM for Jurkat T cells) that 
produce at least 75% cytotoxicity by 24 h exposure. Both primary T cells and Jurkat cells 
display similar kinetics with appreciable losses in cell viability beginning as early as 8 h 
post treatment, and full toxicity effects requiring a longer treatment period of 24 h 
(Figure 7). 
 
ZnO NP Cytotoxicity Is Dependent on Immune Cell Type 
 Our findings of differential ZnO NP toxicity based on cell type (e.g. eukaryotic 
versus prokaryotic) and activation/proliferative potential were extended to determine 
whether NP toxicity might also vary between different primary human immune cell 
types. Comparisons of cytotoxic responses were made between normal T cells, B cells, 
natural killer (NK) cells, and monocytes (Figure 8A). For these studies, freshly isolated 
PBMC cell cultures containing all of these cell types were used, allowing for well-
controlled uniform NP exposure. Following NP treatment for 23-24 h, various cell types 
present in PBMC cultures were identified using Ab specific for T, B, NK or monocyte 
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surface markers and evaluated for toxicity by staining with PI and analyzed by flow 
cytometry.  
 As shown in Figure 8A, differences in NP-induced cytotoxicity are apparent 
between the immune cells present in PBMC samples. CD3
+
 T lymphocytes, CD4
+
 T 
lymphocytes and B lymphocytes display the greatest resistance to NP-mediated 
cytotoxicity and possess a very similar IC50 of ~ 5.0 mM, with no significant differences 
observed at any NP concentration evaluated (0.5 mM, 1 mM, 5mM and 10 mM).  In 
addition, no significant differences were observed between CD4
+
 T cells and CD3
+
 T 
cells (e.g., 97%  1.5% for untreated and 28%  1.7% for 10 mM NP treated vs. 98% 
1.2% for untreated and 34%   3.2% for 10 mM NP, respectively). In contrast, NK cells 
were substantially more sensitive to NP-induced toxicity compared to T and B 
lymphocytes, with an IC50 of 1.0 mM. Statistically significant differences were observed 
between T and B lymphocytes compared to NK cells at NP concentrations of 1 – 5 mM 
(p=0.0028 (T cells) and  p=0.0003 (B cells) at 1 mM, p=0.0002 (T cells) and p= 0.0001 
(B cells) at 2.5 mM, p=0.0019 (T cells) and p=0.0031 (B cells) at 5 mM and p=0.05 at 10 
mM NP).  Most striking is the increased NP-induced cytotoxicity observed in monocytes, 
with >50% of monocytes killed at the lowest NP concentration tested (0.5 mM). 
Statistically significant differences were observed between monocytes and NK cells (0.5 
mM and 1 mM; p=0.0002 and p=0.0008, respectively), and monocytes compared to T 
and B lymphocytes (p<0.0001 for both cell types at both concentrations tested).  
Because adherent monocytes appear considerably more susceptible to NP-induced 
cytotoxicity compared to the other immune cell subsets tested, additional experiments 
were performed testing lower concentrations of ZnO NP on purified monocytes in order 
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to determine the IC50 value.  In these experiments, purified monocytes were treated with 
varying concentrations of ZnO NP (0.0625 mM, 0.25 mM, 0.5 mM and 1 mM) and 
viability evaluated using the fluorogenic redox Alamar Blue cytotoxicity assay. In 
agreement with the monocyte data obtained from PBMC cultures, these results also 
indicate a greater susceptibility to ZnO NP-induced toxicity in monocytes (compared to T 
cells, B cells and NK cells) and reveal an IC50 for monocytes of 0.3 mM (Figure 8B). In 
addition, the Alamar Blue cytotoxicity assay was performed on purified CD4
+
 T cells (1-
10 mM) to confirm results obtained based on PI staining, and a similar IC50 value of 5.4 
was observed (data not shown).   
Although these results indicate that monocytes are considerably more susceptible 
to NP-induced cytotoxicity than other immune cell types tested, it is important to note 
that these apparent differences may be related to significantly different cell culture 
conditions. While T cells, B cells and NK cells grow as suspension cultures, monocytes 
are adherent cells and grow as a monolayer. This difference in growth characteristic may 
be a factor affecting ZnO NP toxicity and thus NP treatments between adherent cells 
versus suspension cells may not be equivalent. Future experiments involving the growth 
of these cell types in 3-dimensional cultures are needed to fully investigate this issue. 
Nevertheless, these results indicate a significant difference in NP toxicity between 
different primary immune cell types, with monocytes showing the greatest susceptibility, 
followed by NK cells which are 3-fold less sensitive than monocytes, and T and B cells 
which are ~ 17-fold and 5-fold less sensitive than monocytes and NK cells, respectively.  
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Size Control of ZnO NP on Immune Cell Viability 
 To evaluate the relationship between ZnO NP size and its toxic potential, three 
different sizes of ZnO NP (4 nm, 13 nm and 20 nm) were concurrently evaluated using 
primary human CD4
+ 
T cells as a model system. The three sizes of NP were made by our 
collaborators by modification of the molar ratio of water to zinc acetate and the shape and 
size confirmed by TEM (Figure 9) (Reddy et al. 2007). A ZnO NP concentration of 5 
mM was chosen for these experiments given the observed IC50 value for T cells. After 24 
h of NP exposure, viability was determined by PI uptake and flow cytometry.  As shown 
in Figure 10A, significantly greater cytotoxicity was observed with 4 nm NP (80.0%  
2.0%) compared to either 13 nm and 20 nm sized NP (p=0.0027 and p=0.0004, 
respectively). Similarly, significantly less cytotoxicity was observed for 13 nm NP 
(70.1%  8.0%) compared to 20 nm particles (44.0%  6.8%, p=0.05). To verify dose-
dependent ZnO NP toxicity based on NP size, we performed experiments testing 4 nm 
versus 20 nm sized NP at varying concentrations (1 mM, 5 mM and 10 mM). As seen in 
Figure 10B, significantly greater toxicity was observed using 4 nm NP compared to 20 
nm NP at all concentrations tested (p=0.015 at 1 mM, p=0.004 at 5 mM and p=0.003 at 
10 mM NP). These results demonstrate that ZnO NP-induced T cell toxicity increases 
with decreasing NP size.  
 Towards understanding the mechanism of this response, it is important to note 
that the band gap energy of NP is shown to increase with decreasing size (Yang, Liu, 
Yang, Zhang and Xi 2009). As a greater band gap energy associated with smaller NP 
could be expected to increase intracellular ROS production, studies were performed to 
address this possibility. However, initial experiments were first performed to establish 
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whether ZnO NP induce ROS production in immune cells and to determine the impact of 
ROS production on cell viability.  
 
ZnO NP Induce ROS Production  
 Several types of nanomaterials, including quantum dots and metal oxide NP, have 
been shown to induce the generation of excess ROS, although only limited studies have 
evaluated the ability of ZnO NP to induce ROS in normal/non-transformed mammalian 
cells (Bergamini et al. 2004; Gojova, Guo, Kota, Rutledge, Kennedy and Barakat 2007). 
To investigate oxidative stress as a mechanism of ZnO NP-induced cellular toxicity, 
studies evaluated ROS production in primary CD3
+
 lymphocytes and CD14
+
 monocytes 
in mixed cell PBMC cultures and in Hut-78 T cancer cells using the cell permeable dye, 
DCFH-DA (Figure 11). In the presence of ROS, including hydrogen peroxide (H2O2) and 
superoxide anion (O2
-
), DCFH-DA is oxidatively modified into a highly fluorescent 
derivative that is readily detectable using flow cytometry. Following ZnO NP treatment 
for 18-24 h, a modest increase in DCFH-DA fluorescence (~7.0 fold increase—
12.5/1.78) was observed in primary lymphocytes treated with 5 mM NP for 18 h (Figure 
11A), and an even stronger induction was observed in Hut-78 T leukemic cells (14-fold 
increase) (Figure 11B). Additionally, peripheral blood monocytes produced robust levels 
(~25.1 fold increase) of ROS in response to ZnO NP, consistent with the greater capacity 
of these cells for ROS generation (Figure 11C). Although increased ROS production was 
detectable as early as 8 h of NP exposure, greater levels were apparent at 18–24 h.  
 To investigate the kinetics of ROS production, PBMC cultures were treated with 
ZnO NP (1 mM and 5 mM) and ROS production measured in T cells and monocytes after 
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6 h and 20 h of NP exposure, using flow cytometry to distinguish between cell types. As 
shown in Table 1, modest amounts of ROS were detectable in monocytes (19% ROS 
producing cells) as early as 6 h post ZnO NP exposure, yet no detectable ROS observed 
in T cells at the corresponding concentration and time point. At 20 h of NP treatment, 
appreciable ROS production was observed in T cells treated with 5 mM ZnO NP (~38% 
ROS producing cells).  Due to nearly complete cell death in monocyte cultures at 20 h 
time points, no residual cell-associated ROS signal was observable.  
 These findings indicate ZnO NP are capable of inducing intracellular ROS in both 
normal healthy immune cells (e.g. T cells and monocytes) and cancerous cells (e.g. Hut-
78), and demonstrate ROS production in monocytes occurs considerably earlier 
compared to T cells. It is important to note that due to differing size and granularity 
properties of the cell types examined, different instrument voltage parameters were 
required which prevents direct comparisons of intrinsic levels of ROS between cell types. 
 
ROS Production Is Dependent on ZnO NP Size 
 As earlier experiments demonstrated a dependence of cell viability on NP size 
(smaller NP display greater toxicity compared to larger NP), we speculated that smaller 
ZnO NP may induce greater amounts of ROS compared to larger NP. The relationship 
between NP size and ROS production was investigated for three different sized ZnO NP 
(4 nm, 13 nm and 20 nm) at two different NP concentrations (5 mM and 10 mM) in 
mixed PBMC cell cultures (Figure 12). Following 3 h of treatment, ROS production was 
evaluated using the ROS detection probe, DCFH-DA and fluorescence measured using a 
microplate reader.  A size dependent induction of ROS was observed at both NP 
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concentrations, with 4 nm sized NP consistently inducing higher levels of ROS compared 
to 13 nm or 20 nm sized NP. At equivalent 5 mM NP concentrations, significantly higher 
levels of ROS were observed for 4 nm and 13 nm NP compared to 20 nm NP (4 -fold 
relative increase (p=0.0165) and 3-fold increase (p=0.05), respectively). Similarly, 10 
mM NP treatment resulted in significant differences in ROS production between all sizes 
of NP with a 3.2-fold greater induction of ROS observed between 4 nm and 20 nm NP 
(p<0.0001), a 1.9-fold increase observed between 13 nm and 20 nm NP (p=0.0297) and a 
1.6-fold increase observed between 4 nm and 13 nm NP (p=0.005).   
 
ROS Quenchers Mitigate ZnO NP-Induced Cytotoxicity 
 Due to the demonstrated ability of ZnO NP to induce ROS production in immune 
cells, experiments were conducted to determine the causal role of NP-induced ROS as a 
major mechanism of toxicity. Purified human CD14
+ 
monocytes and CD4
+
 T cells were 
pre-treated with N-acetyl cysteine (NAC), a tri-peptide that is readily oxidized in the 
presence of ROS, prior to ZnO NP exposure. NAC acts to reduce ROS-induced cell 
damage by augmenting cellular glutathione stores and is a well known ROS quenching 
agent (Valko et al. 2005). Following 24 h of ZnO NP exposure, cell viability was 
assessed using the Alamar Blue cytotoxicity assay and measured using a microplate 
reader. Results reveal that 5 mM NAC significantly protects both monocytes and T cells 
against NP-induced toxicity (p = 0.0001 and p = 0.0481, respectively) and implicates 
ROS formation as a major mechanism of ZnO NP-induced toxicity in primary immune 
cells.  
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NP Association and Uptake 
To evaluate NP-cell interactions, experiments were performed using FITC-doped 
ZnO NP to monitor, quantify and compare NP internalization and extracellular membrane 
association in immune cells.  
 
NP Preferentially Associate with Monocytes Compared to Lymphocytes 
 Based on results indicating monocytes are killed at lower NP concentrations 
compared to the other types of immune cells examined (e.g. T cells, B cells and NK 
cells), we performed experiments to determine if NP cytotoxicity is correlated with the 
degree of NP-cell association and/or NP uptake. Fluorescent FITC encapsulated ZnO NP 
(FITC-ZnO NP) prepared by our collaborators (Wang et al. 2009) were used to quantify 
the extent to which NP physically and stably associate with cells using both flow 
cytometric analysis and confocal microscopy. In one set of experiments, freshly isolated 
PBMCs were treated with 5 mM FITC-ZnO NP, or left untreated, and multi-color flow 
cytometry used to  simultaneous identify monocytes and lymphocyte populations present 
in the PBMC culture, as well as evaluate relative increases in FITC-NP signal in these 
two cell types.  As shown in Table 2, all immune cell types evaluated (T, B, and 
monocytes) show strong NP association, with 78-98% of cells displaying at least some 
level of positive FITC fluorescence compared to control cells cultured in the absence of 
NP.  However, a 9.3-13.7 -fold increase in the number of NP associating with any given 
monocyte compared to individual T and B lymphocytes was observed as indicated by 
changes in the mean fluorescence intensity (MFI) (T and B lymphocytes displayed 
similar MFI values). These results demonstrate that ZnO NP preferentially associate with 
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monocytes (MFI: 131.2) compared to lymphocyte subpopulations (MFI: 9.84 for CD3
+
, 
MFI: 14.1 for CD4
+ 
TH and MFI: 9.61 for B cells), although whether this simply reflects 
initial extracellular membrane-NP interactions or intracellular NP localization is not 
discernable using this experimental approach.  
 
NP Preferentially Associate with Activated T Cells 
Based on differences in activated versus unactivated T cells to ZnO NP-induced 
toxicity and to gain further insights into mechanisms of differential cell toxicity, 
experiments were performed to determine whether NP preferentially associate with 
activated T cells compared to resting T cells. FITC encapsulated ZnO NP (FITC-ZnO 
NP) were prepared as described (Wang et al. 2009) and their fluorescence properties used 
to monitor cell uptake/association. Primary CD4
+
 T cells were both left unactivated or 
activated with CD3/CD28 Ab and treated with 5 mM FITC-ZnO-NP for 4 h. Dual color 
flow cytometry was used to analyze changes in the FITC-NP signal on gated CD4
+
 T 
cells. Results demonstrate a low NP associated fluorescence signal (12.5% FITC 
positive) in resting T cells, while a substantially greater FITC signal (48.4% positive) was 
observed for activated T cells (Figure 14). A dose-dependent uptake/association of FITC-
ZnO-NP was noted with greater NP association at 5 mM compared to 1 mM 
concentrations (3.3 greater attachments at 5 mM).  
At the early time points evaluated in these studies, NP labeling did not appear to 
reflect a generalized increase in membrane permeability as no PI uptake indicative of 
cytotoxicity was observed following 4 h of exposure with 5 mM FITC-ZnO-NP (data not 
shown). However, the expected loss of cell viability (73% ±7.3% s.e., n = 3 with 1.25 
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mM) was detected upon extended 24 h exposure, indicating that FITC ZnO-NP behave 
similarly to unlabeled ZnO NP.  Collectively, these results indicate that the cellular 
processes accompanying T cell activation (e.g. increased membrane protein expression, 
cell cycle progression) result in changes that promote strong physical interactions and 
consequent intracellular uptake of NP. 
 
NP Uptake by Jurkat T Cells 
NP uptake and internalization studies were performed using Jurkat T cells to 
explore NP-immune cell interactions. Jurkat T cells were treated with FITC-ZnO 
particles (green fluorescence) for 8 h, and washed extensively to remove unattached 
extracellular particles and reduce background staining.  Cells were stained with an anti-
CD3 PE-conjugated Ab (red fluorescence) and confocal images taken using live cells to 
avoid internalization artifacts resulting from cell fixation. Figure 15 (panels B-D) shows 
consecutive three-dimensional slices through a single Jurkat T cell and images 
demonstrate internalization of a green fluorescent FITC-ZnO particle with intracellular 
localization being confirmed by viewing along orthogonal directions. Individual confocal 
image slices were taken at intervals of 200 nm thickness (comparable in size to the NP), 
thus only one internalized particle is shown in the presented focal plane. However, at 
least six internalized NP were observed in this particular cell with additional 
internalizations likely but too proximate to the plasma membrane to accurately resolve.   
The presence of such internalized FITC-ZnO particles was confirmed in multiple 
cells present on the culture slide. Figure 15A reflects NP background staining and was 
obtained by treating with an identical concentration of NP and sample washing regime as 
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for cell cultures (Wang et al. 2009). Although these findings do not determine specific 
intracellular locations of the internalized particles, they do demonstrate the ability of 
immune cells to endocytose/phagocytose NP and show a correlation between NP 
internalization/membrane association and susceptibility to ZnO NP-induce cytotoxicity.  
 
ZnO NP Induce Apoptosis 
Published research has demonstrated ZnO NP induce dose-dependent  apoptotic 
and necrotic forms of cell death in non-human mammalian cells, with lower 
concentrations of ZnO NP inducing apoptosis and higher concentrations resulting in 
necrosis (Jeng and Swanson 2006). However, very little is known about ZnO NP-induced 
cell death in human cells, specifically human immune cells. To this end, experiments 
were performed to evaluate mechanisms of ZnO NP-induced cell death (e.g. apoptosis 
and necrosis) in T cells at concentrations previously determined to cause significant cell 
death. Jurkat cells were treated with 0.3 mM NP for 20 h and apoptosis evaluated using 
two different experimental approaches. In the first, cells were stained with a green 
fluorescent annexin V Ab which reacts against externalized phosphatidylserine, a 
characteristic of apoptotic cells, and the red fluorescent propidium iodide dye which 
stains both late-stage apoptotic and necrotic cells displaying permeable membranes 
(Figure 16). As expected, viable control cells show only very weak staining with annexin 
V Ab and no detectable staining with PI (Figure 16 panels A-C). Conversely, cells treated 
with ZnO NP stain positive with the apoptotic marker (e.g. two out of the four cells in 
panel F and four out of five cells in panel G show green fluorescence only). Some dually 
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stained cells were also observed as expected for late-stage apoptotic cells with permeable 
membranes.  
To further verify NP-induced apoptosis, similar cell cultures were stained with the 
DNA dye, acridine orange (Figure 17), which is used to detect apoptotic morphology 
characterized by nuclear fragmentation, cellular shrinkage, and chromatin condensation. 
These morphological changes were observed in NP treated cultures (Figure 17C) and 
cells treated with the apoptosis inducer okadaic acid (Figure 17B), but not in control 
samples (Figure 17A). Collectively, results from these studies indicate ZnO NP toxicity 
to immune cells can occur by an apoptotic process.   
 
ZnO NP Induce Pro-Inflammatory Cytokine Expression 
 The pro-inflammatory potential of NP has been shown to be dependent on a 
variety of factors such as nanomaterial, size, method of delivery, etc. (Duffin, Tran, 
Brown, Stone and Donaldson 2007). To elucidate the pro-inflammatory potential of ZnO 
NP on primary human immune cells, various cytokines (IFN-, TNF-α and IL-12) were 
measured in resting (unactivated) and IFN--primed primary human immune cells. These 
cytokines were chosen because they represent critical pathways involved in both the 
inflammatory response and immune cell activation and differentiation. Freshly isolated 
PBMC were left untreated or treated with varying concentrations of 8 nm ZnO NP for 38 
h. After incubation, cell-free media was harvested and cytokine levels measured using an 
ELISA assay (performed by Cytokine Core Laboratory, Baltimore, MD). Additionally, 
some cell samples were primed with IFN- (1000 U/mL) before addition of NP to assess 
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the effect of activation status on cytokine production (specifically, IL-12) in response to 
NP treatment.  
 Results from these studies demonstrate significant dose-dependent increases in 
IFN- and TNF-α in response to ZnO NP treatment at all concentrations tested (0.05 mM, 
0.1 mM and 0.2 mM) (Figure 18A and B). Interestingly, while ZnO NP treatment did not 
induce appreciable amounts of IL-12 production in resting cells, significant dose-
dependent increases were observed in IFN--primed cells (Figure 18C). The inability of 
ZnO NP to induce IL-12 in resting cells is not altogether surprising as naturally occurring 
IL-12 production is typically only seen in antigenically activated immune cells (e.g. DC, 
monocytes, T cells) (Maranda and Robak 1998). These findings indicate ZnO NP are 
capable of inducing at least some key components of inflammation, and further suggests 
that a Th1-mediated immune response may be elicited, which is the type of immunity 
desirable for eradicating cancer and virally infected cells (Tau et al. 2000). 
   
SnO2 NP and CeO2 NP Appear Less Toxic to T Cells Compared to ZnO NP 
 Initial experiments were performed to compare ZnO NP toxicity in T cells to two 
other common types of metal oxide NP, namely SnO2 NP and CeO2 NP (Figure 19). 
CD4
+
 T cells were left untreated or treated with 10 mM NP of either SnO2 NP or CeO2 
NP for 22-24 h and dual color flow cytometry was used to simultaneously identify cells 
and test cell viability using PI. Preliminary findings indicate both SnO2 NP and CeO2 NP 
fail to kill T cells at 10 mM of NP treatment (90% viability), a concentration shown to 
cause significant ZnO NP-induced T cell death (<30% viability, Figure 8A). 
Interestingly, treatment with SnO2 NP and CeO2 NP caused a dramatic increase in cell 
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granularity (SSC) with no concurrent change in size (FS), and gating on these highly 
granular cells revealed an absence of PI signal, indicating normal cell viability. As 
increases in granularity (SSC) properties with no concurrent change in size (FS) may be 
indicative of phagocytosis/endocytosis (Coester, Nayyar and Samuel 2006; Elamanchili, 
Diwan, Cao and Samuel 2003), these preliminary results suggest SnO2 NP and CeO2 NP 
are taken up by T cells, but unlike ZnO NP, may not cause appreciable cell death. 
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DISCUSSION 
 
Nanomaterials are of particular interest due to the unique physical, chemical and 
biological properties that can accompany reduction to the nanoscale (Medina, Santos-
Martinez, Radomski, Corrigan and Radomski 2007). Unlike micron-sized bulk materials, 
the properties of nanomaterials are governed by principles of both classical and quantum 
physics and are attributed, at least in part by an increased surface area to volume ratio 
with decreasing size. This translates into distinctive size-dependent characteristics, and 
much research is devoted to gaining an understanding of how these characteristics impact 
biological and cellular systems (Fortina, Kricka, Surrey and Grodzinski 2005). 
   NP are being explored for a variety of different biomedical applications and are 
already found in many commercial products. Metal oxide NP, specifically ZnO NP, are 
one such type of NP frequently used in sunscreens and cosmetics due to its increased 
transparency and enhanced UV protection (Fan and Lu 2005). ZnO NP are also 
recognized as semi-conductor quantum dots, which are a class of NP which exhibits size-
dependent fluorescent properties that render them useful in biosensing (e.g. tumor 
detection) and enhanced tissue imaging (Bawarski, Chidlowsky, Bharali and Mousa 
2008). Understanding how NP interact and impact cells is of critical importance from an 
environmental health and safety standpoint, and also may provide for novel NP 
applications. 
Research has provided evidence that specific properties such as size, shape and 
surface reactivity all contribute the cytotoxic potential of NP (Igarashi 2008). Our results 
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demonstrate differences in ZnO NP-induced toxicity to immune cells based on several 
parameters such as cell type, cell activation status, proliferative potential, NP size, the 
extent of NP-cell physiological interactions, and implicate ROS production as a major 
mechanism of cytotoxicity. Additionally, results indicate ZnO NP elicit pro-inflammatory 
cytokine production from immune cells. Collectively, these findings illustrate differential 
ZnO NP effects and suggest a potential clinical relevance for ZnO NP in the treatment of 
diseases such as cancer and autoimmunity based on the cell-selective cytotoxic properties 
of these NP.  
 
We first evaluated the effect of ZnO NP compared to larger micron-sized ZnO on 
purified human CD4
+
 T cell viability as a representative immune cell type due to the 
important role of T cells in regulating the immune response. Our findings demonstrate 
dose-dependent decreases in cell viability in response to ZnO NP treatment at 
concentrations of bulk ZnO where no appreciable loss in viability is observed (Figure 2). 
These results indicate that when reduced to the nano-scale, ZnO acquires unique size 
dependent properties resulting in altered toxicity thresholds compared to what is typically 
observed for this bulk material. To further explore this issue, T cell results were 
compared to ZnO NP studies performed by our collaborators, Drs. Kevin Feris and Alex 
Punnoose, showing bacteria (E. coli and S. aureus) inhibition in response to ZnO NP 
treatment, and reveal both types of bacteria are killed at lower concentrations compared 
to T cells (data not shown, p<0.0001) (Reddy et al. 2007). Although there were 
differences in certain experimental conditions between the bacteria and T cell studies, 
including media type (i.e. LB for bacteria and RPMI for T cells) and vehicle type for NP 
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delivery (i.e. DEG for bacteria and PBS for T cells), results are still of interest as both 
types of culture media contain large proteins, carbohydrates and other factors which 
might influence NP toxicity and no appreciable vehicle effect was observed for either cell 
type in control cells. Our studies further demonstrate that differences in NP-induced 
cytotoxicity exist between types of common bacteria, with S. aureus being more 
susceptible than E. coli (Figure 3) (Reddy et al. 2007).  These differences in NP 
susceptibility observed among bacteria strains and between bacteria and human cells 
suggest the possibility of exploiting ZnO NP for use as novel anti-microbial agents in 
which potentially harmful bacteria are selectively eliminated and normal human cells are 
spared.  As such, future research is necessary to build on these findings for further 
elucidation of factors underlying ZnO NP cytotoxicity and investigating ZnO NP effects 
on other types of bacteria.   
 
To further explore mechanisms underlying differential ZnO NP cytotoxicity, we 
extended our studies to investigate whether the activation status of immune cell 
influences toxicity. CD4
+
 T lymphocytes were utilized as a representative cell type given 
their critical role in protective immunity, the frequent negative effects of commonly used 
chemotherapeutic agents on cells of hematopoietic lineage, and the ability of self-reactive 
T cells to contribute to the development of autoimmune diseases. ZnO NP- cell responses 
were evaluated in normal primary resting T cells and compared to identical cultures in 
which cells were either activated through the T cell receptor (TCR) signaling pathway or 
via both TCR and CD28 co-stimulation pathways. Results demonstrate significantly 
greater resistance to ZnO NP-induced toxicity in quiescent T cells compared to TCR 
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stimulated cells, and even greater sensitivity in TCR/CD28 co-stimulated T cells (Figure 
4). Additionally, we found activated T cells associate with ZnO NP to a greater extent 
compared to resting T cells (Figure 14), consistent with the greater susceptibility to ZnO 
NP-induced toxicity in activated cells compared to resting cells. The preferential killing 
and greater NP association observed in activated cells relative to quiescent cells of the 
same lineage suggests that mechanisms of ZnO NP toxicity may be related to the 
proliferative potential of the cell and subsequent NP-cell interactions. In a number of 
autoimmune diseases, including multiple sclerosis and psoriasis, self-reactive T cells are 
a pathogenic subset underlying disease processes and exist in a predominately activated 
state as they are continually exposed to specific Ag present in normal body tissue 
(Wagner 2007). Because only a very small percentage of the total T cell repertoire are 
self-reactive and pathogenic in autoimmunity, the ability of identical concentrations of 
ZnO NP to preferentially induce cytotoxicity in self-reactive activated T cells while 
leaving the unactivated T cell repertoire largely intact and immunity uncompromised 
represents an incredibly attractive approach for treatment. Thus, these findings may 
provide a foundation for the development of ZnO NP-based therapeutics, where disease-
causing cells are targeted by attachment of Ab to ZnO NP directed against proteins 
expressed predominantly on activated T cells, such as CD40L and OX40 (Taraban et al. 
2002). However, additional research is required to further elucidate factors influencing 
NP toxicity and in vivo studies are necessary to gain a more thorough understanding of 
how ZnO NP impact the immune system as functioning unit. 
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The greater toxicity of ZnO NP against activated T cells led to experiments 
testing the effects of ZnO NP toxicity in memory versus naïve T cells (Figure 6), since 
memory T cells are recognized to respond and proliferate much faster to a previously 
encountered Ag compared to naïve (Surh and Sprent 2008). For these experiments, bulk 
cultures of PBMCs were treated with ZnO NP and T cell types  present in PBMC cultures 
(naïve, memory and a mixture of both) identified by cell-surface markers. Our results 
demonstrate that memory T cells are more susceptible to ZnO NP-induced cytotoxicity 
compared to antigenically inexperienced naïve T cells, and support the hypothesis that 
ZnO NP toxicity is dependent on the metabolic status and proliferative capacity of the 
cell.  
 
Differences in ZnO NP cytotoxicity based on cell type (e.g. prokaryotes versus 
eukaryotes) and cell activation status lead to experiments in which normal cells were 
compared to cancerous cells of the same lineage, as cancer cells exhibit uncontrolled 
proliferation and robust metabolic activity (Hanley et al. 2008). Results reveal that 
cancerous T cells are markedly more susceptible (~28-35 times) to ZnO NP mediated 
toxicity compared to their normal counterparts (Figure 5), and similar kinetics were 
observed for NP-induced toxicity to both cancer and normal T cells (Figure 7).  These 
findings may be of clinical importance as one of the greatest challenges facing 
chemotherapy is the inability of anticancer drugs to effectively distinguish between 
normal and transformed tissue (Nie, Xing, Kim and Simons 2007; Hellman 1980).  
Although many commonly used chemotherapeutic drugs target rapidly dividing cells, 
many suffer from a relatively low therapeutic index, that is, the ratio of toxic dose to 
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effective dose (Huang and Oliff 2001). This limitation frequently causes a broad range of 
toxicities leading to dose limiting toxicity and a concomitant reduction in antitumor 
efficacy. The preferential toxicity of ZnO NP towards cancerous T cells is of substantial 
magnitude, especially in comparison to ex vivo indices reported for other commonly used 
chemotherapeutic agents using similar cell viability assays. For example, therapeutic 
indices of  ≤ 10 have been reported for two commonly used chemotherapeutic agents,  
doxorubicin and carboplatin, against a variety of tumors including acute myelogenous 
leukemia, non-Hodgkin’s lymphoma, ovarian, and other solid tumors (Bosanquet and 
Bell 2004).  Additionally, the similar kinetics observed in cancer and normal T cells 
suggests ZnO NP-induced cytotoxicity occurs in a predictable time-dependent fashion, 
regardless of cell type and susceptibility (Figure 7), and is a critical piece of information 
when considering materials for drug development.  
The inherent differential toxicity of ZnO NP against activated and rapidly 
dividing cancer cells raises exciting opportunities for their potential use as anticancer 
agents, and the selectivity of these nanomaterials may be further enhanced by the 
covalent attachment of monoclonal Ab, peptides, and small molecules to tumor-
associated proteins which would allow for selective targeting of the disease-causing 
cancer cells for in vivo studies using animal models.  However, care must be taken when 
extrapolating these observed differential cell responses to all cell types until further 
studies have been conducted evaluating the effects of ZnO NP across many cell lineages.  
 
The preferential ZnO NP-induced killing of highly proliferative cancer cells and 
activated T cells indicates a need to examine the effects of ZnO NP toxicity on various 
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types of resting primary immune cells. To assess this, the effect of ZnO NP on cell 
viability was measured in primary human T cells, B cells, NK cells and monocytes in 
mixed PBMC cell cultures and cell identification achieved by labeling cell-specific 
surface markers. Testing the effects of ZnO NP in bulk immune cell cultures is 
advantageous, as it takes intercellular interactions and cell-signaling effects into account, 
and is a better estimation of in vivo effects and physiological relevancy. Of the four cell 
types tested, monocytes were shown to be the most susceptible to ZnO NP-induced 
toxicity, with 18-fold and 6-fold differences in viability observed compared to T and B 
lymphocytes and NK cells, respectively (Figure 8). As immune cells are highly diverse 
and possess unique phenotypes based on specific immune cell function, our findings 
indicate ZnO NP toxicity may be dependent on differences in cell-specific properties 
such as growth characteristics, size, cell-surface receptors, mechanisms of particle 
uptake, capacity for ROS production, etc. 
 For example, unlike T, B, and NK cells which grow in vitro as free floating cell 
suspensions, monocytes are an adherent cell type and grow in culture as a surface 
monolayer. This property may influence the effective concentration of ZnO NP treatment 
for adherent monocytes as NP aggregates form and settle on top of the monocyte layer. 
Future studies are needed to determine the extent to which these differing attributes (e.g. 
adherence versus suspension) contribute to ZnO NP toxicity, and one potential approach 
would be altering adherent cell methodology by growing adherent cells on a 3-
dimensional structure within culture media before ZnO NP addition.  
Additionally, physiological differences between phagocytes and non-phagocytic 
cells, such as increased particle uptake by phagocytes, larger phagocyte size, and greater 
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capacity for ROS formation (generated for intracellular destruction of bacteria in the 
phagosomes) may help to explain increased ZnO NP susceptibility in monocytes 
compared to lymphocytes. Phagocytes may be more likely to ingest NP aggregates, and 
the larger cell size may allow more room for intracellular NP accumulation, and 
consequently, increased intrinsic ROS production. As monocytes already produce greater 
levels of ROS compared to lymphocytes, excess ROS generated in response to NP 
exposure may result in overwhelming oxidative stress mechanisms leading to cell death. 
The production of ROS may also factor into why NK are killed at lower concentrations of 
ZnO NP compared to T and B lymphocytes as published research indicates that ROS is 
used by cytotoxic NK cells for induction of caspase-independent induced target cell 
killing (Martinvalet, Zhu and Lieberman 2005), although additional research is required 
to substantiate this hypothesis.  
 
Although phagocytosis is not a major defense mechanism used by T, B and NK 
cells, these cells are capable of intracellular uptake of certain particulate matter by 
endocytosis (e.g. pinocytosis and receptor-mediated endocytosis), which is used by all 
cells for accessing macromolecules and other essential molecules, and trafficking of cell 
surface receptors (Rogers and Basu 2005).  To explore whether increased ZnO NP 
sensitivity is correlated with NP uptake and association, fluorescent FITC-doped ZnO NP 
were used to investigate NP-cell interactions. Consistent with our toxicity findings, 
observations reveal both T cells (Figure 15) and monocytes capable of NP uptake, and 
demonstrate greater NP association in monocytes compared to both T and B lymphocytes 
(Table 2). Although exact mechanisms by which nonfunctionalized NP (NP without 
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functionalized localization or target sequences), such as ZnO NP, interact with cells is not 
yet fully understood, several studies have provided evidence that both negatively and 
positively charged NP (specifically QD) can be endocytosed by human cells and are 
capable of nuclear penetration (Ryman-Rasmussen, Riviere and Monteiro-Riviere 2007; 
Jaiswal, Mattoussi, Mauro and Simon 2003). Based on these findings, future experiments 
are warranted to investigate exact mechanisms of ZnO NP uptake and association 
between different cell types. 
Our results support other studies showing significantly greater NP QD (CdTe and 
CdSe/ZnS) uptake in phagocytic cells compared to NP uptake by non-phagocytic cells, 
and indicate that specific structural and physiological differences between different 
immune cell types, such as adherence and phagocytic ability, significantly contribute to 
ZnO NP-induced toxicity, allowing for predictions of increased NP susceptibility based 
on these characteristics for other cell types. The extent to which cells internalize and 
associate with ZnO NP may be an essential component of selective ZnO NP toxicity and 
although specific mechanisms of ZnO NP cellular uptake cannot be determined from 
these experiments, existing research indicates QD are capable of exploiting the cell’s 
active transport machinery for NP delivery to discrete intracellular and intranuclear 
destinations (Nabiev et al. 2007). Future research directed at exploring specific 
mechanisms of ZnO NP uptake such as the contributions of receptor-mediated compared 
to non-receptor mediated endocytosis and factors influencing NP uptake (e.g. NP charge, 
dissolution, NP size, etc.) may shed further light on this issue.   
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Oxidative stress, as seen in excessive ROS production, is implicated in 
degenerative and detrimental biological processes such as aging and disease development 
(e.g. cancer, Alzheimer’s disease), and a number of studies indicate that certain 
nanomaterials, including metal oxide NP, have the potential to exhibit spontaneous ROS 
production based on material composition and surface characteristics, while other 
nanomaterials trigger ROS production only in the presence of select cell systems  (Xia et 
al 2006; Lovric, Cho, Winnik and Maysinger 2005; Long, Saleh, Tilton, Lowry and 
Veronesi 2006). Results from our flow cytometry experiments demonstrate ZnO NP 
induce ROS production in both primary and cancer immune cells (specifically T cells and 
monocytes) and are consistent with other reports demonstrating ROS production in biotic 
environments following ZnO NP exposure (Xia et al. 2008b). Our findings show ZnO 
NP-induced ROS formation occurs in a concentration, time, and cell-type dependent, 
with higher levels observed in primary monocytes compared to primary T cells, which is 
consistent with the ability of these cells to generate large amounts of ROS during an 
immune response. Interestingly, immortalized T cells produced greater levels of ROS 
than primary T cells which may mechanistically underlie the greater susceptibility of 
cancerous T cells to NP-mediated toxicity (Figure 11).  
These findings have important implications regarding mechanisms of cellular 
toxicity, as elevated ROS production that exceeds the capacity of the cellular antioxidant 
defense system causes cells to enter a state of oxidative stress which results in damage of 
cellular components such as lipids, proteins, and DNA (Lovric et al. 2005; Xia et al. 
2008b). NP-induced ROS production may activate transcription factors such as NK-kB 
and AP-1 that control the transcription of pro-inflammatory genes (Monteiller et al. 
79 
 
2007), however, it is still enigmatic under which conditions cellular demise induces an 
immune response or remains immunologically silent, and under which circumstances 
apoptotic or necrotic cells are immunostimulatory or tolerogenic (Kepp et al. 2009).  
 
The causal role of ROS generation in NP-mediated cytotoxicity was validated by 
experiments using the ROS quencher, NAC. Results from these experiments 
demonstrated significantly greater viability in cells (e.g. primary monocytes and CD4
+
 T 
cells) pre-treated with NAC before NP treatment compared to cells treated with NP alone 
(Figure 13). These results provide important insights implicating ZnO NP-induced ROS 
production as a primary mechanism of immune cell cytotoxicity and led to studies 
investigating the effect of NP size on ROS production.  
 
Nano-scaled particles exhibit discontinuous crystal planes, increases in structural 
defects and changes in the electronic configuration, resulting in altered electronic 
properties on the particle surface which are directly related to particle size (Oberdorster et 
al. 2005). We evaluated the effect of ZnO NP size on immune cell toxicity and ROS 
production using 3 different sizes of ZnO NP (4 nm, 13 nm and 20 nm) at multiple 
concentrations. Findings from our studies demonstrate an inverse relationship between 
ZnO NP size and immune cell viability (Figure 10) which is consistent with reports using 
other NP systems and materials showing greater cytoxicity associated with smaller NP 
size (Nair et al. 2008). In agreement with our toxicity results, we found smaller ZnO NP 
(4 nm) induce greater amounts of ROS in immune cells compared to larger ZnO NP (e.g. 
20 nm) (Figure 12) which may be due to smaller particles having larger reactive surface 
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areas compared to larger particles (Nel, Xia, Madler and Li 2006). In general, biological 
activity increases with decreasing particle size and the opposing trend of increased 
toxicity and ROS production with decreasing NP size indicates that if ZnO NP were to be 
employed for use in therapeutics, the smallest NP size available should be considered for 
use.  
Particle size, shape, and chemical composition have been shown as principal 
factors controlling NP-cellular interactions and toxicity to mammalian cells (Yang et al. 
2009). Another factor shown to contribute to the intracellular interactions with NP and 
NP-induced cytotoxicity is the dissolution of ions from metal and metal oxide NP, 
although the extent to which ion dissolution contributes to NP toxicity is unclear (Gojova 
et al. 2007; Cheng 2004). The dissolution of copper, cadmium and zinc ions from NP 
have been shown as major contributors in NP-induced toxicity to mammalian cells, 
especially in low pH conditions, and increasing ion dissolution has been correlated with 
decreasing particle size (Midander et al. 2009; Wang, Nagesha, Selvarasah, Dokmeci and 
Carrier 2008; Aruoja, Dubourguier, Kasemets and Kahru 2009). In one study, researchers 
found dissolution to play a significant role in ZnO NP-induced toxicity by disturbances in 
cellular zinc homeostasis resulting in lysosomal and mitochondrial damage and 
subsequent cell death (Xia et al. 2008a). However, conflicting research demonstrates 
minimal effects of Zn
2+
 ion dissolution alone on cell viability, and indicates NP size and 
surface chemistry as significant determinants of NP-induced toxicity (Yang et al. 2009) 
by ascribing the toxicological effects of ZnO NP not to particle dissolution, but to 
specific NP surface properties as determined by chemical composition (Yang et al. 2009). 
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The effects of NP size on toxicity have also been shown to be related to NP 
uptake (smaller NP are internalized to a greater extent compared to larger NP) and 
mitochondrial membrane association (Yang et al. 2009; Tarantola et al. 2009).  The 
inconsistencies that currently exist in the scientific literature indicate that additional 
studies are warranted in these areas. Nonetheless, our research supports other studies by 
demonstrating a dependency of cytotoxicity on NP size and is novel in showing these 
effects specifically using ZnO NP in primary human immune cells.  
The reduction in size of many materials to the nano-scale increases toxicity in 
many types of materials; however research suggests that other types of materials have 
cytoprotective properties at the nano-scale. We performed initial experiments to test 
differences in toxicity between CeO2 NP and SnO2 NP to primary T cells for comparison 
to results obtained using ZnO NP (Figure 19). Results from these preliminary 
experiments suggest that unlike ZnO NP, CeO2 and SnO2 are not toxic at 10 mM NP 
treatment, however, the increased granularity observed in response to NP treatment 
suggests NP uptake. These findings are in agreement with other published reports 
evaluating the effects CeO2 NP on mammalian cells where it is hypothesized that the 
antioxidant properties of CeO2 NP suppress ROS production and exert cellular resistance 
to exogenous sources of oxidative stress, thus protecting cells from oxidative injury 
(Chen, Patil, Seal and McGinnis 2006; Tarnuzzer, Colon, Patil and Seal 2005). Although 
suggestive, more research is required to further explore this issue as well as testing the 
effects of additional types of metal oxide NP on human immune cells. 
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As there is increasing evidence that elevated ROS acts as a critical signaling 
molecule in the induction of apoptosis by various stimuli (Jeng and Swanson 2006), 
studies were performed to determine mechanisms of ZnO NP-induced cell death.  Results 
presented in Figures 16 and 17 provide strong evidence that ZnO NP cytotoxicity occurs 
by apoptotic processes in cells of T lymphocyte lineage at the concentrations tested. 
Research suggests the amount of ROS produced and intensity of oxidative stress may 
determine mechanisms of cell death, specifically selection between apoptosis and 
necrosis, with higher levels of ROS associated with the latter (Baigi et al. 2008). In 
contrast to apoptotic processes, necrotic forms of cell death are generally considered 
immunostimulatory (e.g. capable of eliciting a comprehensive immune response) and 
pro-inflammatory. However, the conditions under which cellular demise is 
immunostimulatory (e.g. elicits a comprehensive immune response) are not yet fully 
understood and controversy exists over whether apoptotic or necrotic cells are 
intrinsically immunogenic or tolerogenic (Kepp, Tesniere, Zitvogel and Kroemer 2008). 
Recent evidence indicates that in contrast to scientific dogma concerning 
apoptotic cellular mechanisms, apoptosis (especially late stage apoptosis) may not be  
morphologically homogenous as evidenced by the surface expression of several proteins 
shown to promote antigen presentation and subsequent immune cell activation (Kepp et 
al. 2008). Distinguishing mechanisms of cell death (e.g. apoptosis versus necrosis) is a 
critical component of drug development as moderate levels of immune cell activation are 
beneficial for eliminating disease-causing cells, such as tumor cells, while over-
stimulation of the immune response has been shown to promote tumorgenesis.  
83 
 
These studies indicate that a primary mechanism of ZnO NP cytotoxicity may 
precede ROS generation which then underlies the induction of apoptosis, a process that 
may be prevented by antioxidant and ROS quenchers. These observations may provide 
the basis for the development of new rational strategies to protect against ZnO NP 
toxicity or enhance the desired destruction of pathogenic cell types. Further research is 
needed to establish if the mechanism of ZnO NP-induced cell death (e.g. apoptosis or 
necrosis) occurs in a dose-dependent manner if this material is to be considered for 
therapeutic purposes as manipulation of this property may allow for more effective 
elimination of diseases-causing cells.  
 
Certain metal oxide NP have been shown to induce pro-inflammatory responses, 
and some cytokines have been reported as induced by various metal oxide NP (Park and 
Park 2009). Additionally, the relationship between oxidative stress and inflammation is 
well established and studies have provided evidence which suggests ROS-induced 
inflammatory responses play a critical role in the cytotoxic effects (both apoptotic and 
necrotic) of different types of NP both in vitro and in vivo (Johar et al. 2004). We 
evaluated the effect of several different concentrations of ZnO NP on the expression of 
three different pro-inflammatory cytokines, IFN-, TNF-α, and IL-12, using bulk cultures 
of PBMCs. The role of TNF-α in inflammation is well characterized and has been shown 
to be an important regulator of acute inflammation, capable of influencing many aspects 
including infiltration of inflammatory cells into tissue, activating phagocytosis, inducing 
apoptosis in virally infected and tumor cells, chemotaxis of monocytes, and promoting 
Th1 differentiation. Notably, this cytokine received its name by the potent anti-tumor 
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activity it possesses when used at appropriate concentrations. However, high levels and 
chronic exposure to TNF-α have been shown to be detrimental and are associated with 
many of the symptoms associated with autoimmune disease. Our results demonstrate 
significant dose-dependent increases in TNF-α in response to ZnO NP compared to 
control cultures (Figure 18B). This dose-dependent response is important when 
considering ZnO NP for biomedical purposes as it allows for controlling the levels of 
TNF-α needed to achieve therapeutic responses without eliciting the potential damaging 
effects of TNF-α.  
IFN-, secreted primarily by activated T cells, was also evaluated and is another 
cytokine associated with inflammation and Th1 differentiation. Similar to what was 
observed for TNF-α, our results demonstrate dose-dependent increases in IFN- in 
response to ZnO NP (Figure 18A). This provides further evidence that ZnO NP can 
induce pro-inflammatory, Th1-directed immune responses at concentrations below those 
required to produce significant losses of T cell viability. These results are important as 
IFN- is an important cytokine for promoting a Th1-mediated immune response, and Th1 
cells are recognized as an essential cell subset for the effective elimination of cancer cells 
in vivo. The narrow range in ZnO NP concentrations necessary to increase TNF-α and 
IFN- reveals that parameters controlling ZnO NP toxicity, such as size, concentration, 
etc. need to be carefully controlled if ZnO NP are to be considered for used for 
therapeutic purposes.  
The cytokine IL-12 is secreted primarily by activated monocytes, macrophages, 
DC cells, and to a lesser extent, T cells. IL-12 is essential in skewing the Th1/Th2 T cell 
responses toward a Th1-cell mediated immune response by inducing NK cells and T cells 
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to secrete other Th1-directed cytokines and suppressing the humoral Th2-mediated 
cytokines.  Results from these experiments reveal that when PBMC are first primed by 
addition of exogenous IFN-, significant increases in IL-12 are observed in response to 
NP treatment (Figure 18C). These results suggest that a synergistic relationship between 
ZnO NP and the priming signals necessary to promote IL-12 secretion (e.g. IFN-) may 
occur in in vivo settings employing ZnO NP.  
Importantly, our findings demonstrating that ZnO NP can induce TNF-α, IFN-, 
and IL-12 in activated immune cells suggest that careful titration of ZnO NP-based 
therapeutic interventions may be successful in elevating this key group of cytokines 
important for eliciting a Th1-mediated immune response with effective anti-cancer 
actions. Our results support other research demonstrating ZnO NP capable of inducing 
other pro-inflammatory cellular responses (Gojova et al. 2007; Sayes et al. 2007; Wieder 
et al. 2008), however this research is limited and to date, there have been no reports in 
which the pro-inflammatory potential of ZnO NP in primary human immune cells have 
been evaluated. Our results are of interest as they suggest the possibility of manipulating 
the immune response for utility in enhancing cancer cell targeted killing at concentrations 
of ZnO NP that do not cause significant cell death to normal cells.   
 
In conclusion, results from these studies provide evidence demonstrating ZnO NP 
induce toxicity in a cell-specific and proliferation dependent manner with rapidly 
dividing, higher-ROS producing cells being the most susceptible, presumably in response 
to intracellular NP-mitochondrial interactions and mitochondrial damage, and quiescent 
cells being the least sensitive. Results also indicate cell-type dependent NP association 
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and intracellular localization, although additional research is required to further elucidate 
selective phagocytic/endocytic ZnO NP mechanisms based on specific cell susceptibility 
to ZnO NP-induced toxicity. ZnO NP increased the expression of the pro-inflammatory 
cytokines IFN-, TNF-α, and IL-12 at concentrations that shown minimal toxicity to 
primary NK, T and B cells. Manipulation of the immune response is a key element for the 
effective treatment of disease, and many current treatments for cancer, infection and 
autoimmunity are immunobased therapeutics (Becker 2006; Miao 2007).These findings 
suggest ZnO NP may direct Th1 mediated immune responses in vitro and illustrate the 
potential utility of ZnO NP for the treatment of diseases such as cancer, which is better 
eradicated by the development of a vigorous Th1-mediated immune response. Future 
studies will be required to investigate the effects of higher concentrations of ZnO NP on 
pro-inflammatory cytokine secretion and evaluate NP effects on other cytokine profiles. 
Additionally, expansion of these studies should include investigating mechanisms of ZnO 
NP adsorption, specifics of cellular uptake and intracellular localization, and the 
contribution of particular elements of the biotic environment that affect ZnO NP toxicity. 
Collectively, the findings presented in this research provide significant information that 
may be ultimately exploited for utilizing ZnO NP in the treatment of disease and 
developing next generation NP-based nanomedicines leading to improvements in 
lifespan, tumor growth inhibition, and decreased lethality. 
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APPENDIX  
Figures and Tables 
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Figure 1. Transmission electron microscopy (TEM) image and size distribution of ZnO 
NP. A) For experiments conducted on all eukaryotic cells, ZnO NP were spun out of 
DEG, washed with ethanol, dried into powder form, and resuspended in an aqueous 
phosphate buffered saline (PBS) solution to desired stock concentration (mM). B) Plot 
showing particle size distribution where average NP size was determined to be 13 nm.
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 Figure 2.  Effect of micron-sized bulk ZnO versus ZnO NP on CD4
+
 T cell 
viability. Purified CD4
+
 T cells (>96%) were cultured at 1 x 10
6
 
cells/mL and treated with 
varying concentrations of 13 nm ZnO NP or bulk ZnO. After 24 h of culture, cells were 
dually stained with PI and a FITC-labeled anti-CD4 antibody. 10,000 events gated on 
CD4
+
 T cells were analyzed for changes in PI staining to allow quantification of cell 
death. NP were excluded from analysis based on their absence of fluorescent signal. Data 
from four independent experiments is presented and error bars depict standard error. To 
assess differences in viability between bulk ZnO and ZnO NP at each concentration, data 
was analyzed using a repeated measures analysis of variance (ANOVA) and asterisks 
denote statistically significant differences (p <0.05). 
 
 
 
  
 
 
 
 
90 
 
 
 
 
 
 
 
 
 
Figure 3. Dot plots of relative viability of bacterial suspensions by flow cytometry. 
Samples of bacteria were prepared, stained and analyzed using a 2-color live/dead 
BacLight
®
 viability kit allowing for a two-parameter comparison of green and red 
fluorescence emission. Prior to sample analysis, the assay was validated using known 
mixtures of dead and live control cells. Bacteria were gated by forward scatter and side 
scattering light properties (R1, not shown) and nanoparticles excluded from analysis 
based on their absence fluorescence (R2, not shown). The R3 region depicts the region 
containing dead cells and the R4 region depicts the region containing live cells. A) The 
relative viability of E. coli (>30% loss of viability) treated with 5 mM ZnO nanoparticles 
for 15 h. B) The relative viability of S. aureus (>59% loss of viability) treated with 2 mM 
ZnO nanoparticles for 15 h.  
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Figure 4. ZnO NP toxicity to unactivated and activated primary human CD4
+
 T cells. A) 
Human peripheral blood CD4
+ 
T cells were isolated (purity >95%) and activated with 
anti-CD3 antibodies, a combination of anti-CD3 and anti-CD28, or left unactivated.  
Cultures were concurrently treated with varying concentrations of ZnO NP for 22-24 h 
and cell viability determined using flow cytometry and PI uptake (means  standard 
error, n=6). To evaluate the relationship between cell cycle state and ZnO NP toxicity, 
data was analyzed using repeated measures analysis of variance and model based means 
post hoc test (p < 0.05). The two study factors are cell cycle state (unactivated, 
moderately activated with anti-CD3, and fully activated with anti-CD3/anti-CD28) and 
ZnO NP concentration (0 mM, 1 mM, 5 mM and 10 mM). Following overall statistical 
significance, cell viability (%) was compared among activation states at each 
concentration level using model-based estimates and standard errors. B) Verification of T 
cell activation was determined by concurrently monitoring expression of membrane 
CD40L protein using flow cytometry (means  standard error, n=5). 
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Figure 5. Differential cytotoxic effects of ZnO NP on cancerous T cell lines and primary 
T cells. A) Jurkat, Hut-78 T cell lines, or normal primary T cells were treated with 
varying concentrations of ZnO nanoparticles for 22–24 h and viability determined by 
monitoring PI uptake using flow cytometry. Data from seven (Jurkat), three (Hut-78), and 
four (normal CD4
+
 T cells) independent experiments is presented and error bars depict 
standard error. Data was analyzed using a repeated measures ANOVA and model based 
means post test. Statistical comparisons were made between each cancer cell line and 
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primary T cells at 0.1 and 0.5 mM ZnO NP with significance levels defined as p < 0.05 
and indicated by an asterisk. B) Jurkat and primary T cell viability was assessed using the 
LIVE/DEAD
™
 Viability/Cytotoxicity Kit for mammalian cells (Invitrogen, Eugene, OR). 
Following ZnO NP exposure for 24 h, cells were stained with calcein AM (green 
fluorescence) and ethidium homodimer-1 (red fluorescence) to differentiate between live 
and dead cells, respectively. Data from a representative experiment is presented with 
error bars depicting standard error, n = 3. A two-way analysis of variance combined with 
a model based means test indicates significant differences in viability between Jurkat and 
primary T cells for all NP concentrations tested (asterisk denotes p < 0.0001). 
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Figure 6. Differential ZnO NP cytotoxicity between naïve and memory T cells. Human 
peripheral blood PBMC were left untreated or treated with 10 mM ZnO NP (8 nm) for 
22-24 h and viability determined by monitoring PI uptake using flow cytometry.  T cells 
were defined as CD3
+
, naïve T cells as CD3
+
, CD45RA
+
, and memory T cells as CD3
+
, 
CD45RO
+ 
events.  Data from three independent experiments is presented and error bars 
depict standard error. Asterisks denote statistically significant differences (p < 0.05) 
between NP treatment groups as determined using as a one-way repeated measures 
ANOVA.   
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Figure 7. Kinetics of ZnO NP toxicity on normal primary T cells and Jurkat T leukemia 
cells. Freshly isolated CD4
+
 T cells (purity > 96%) were treated with 10 mM ZnO NP  
and Jurkat T cells were treated with 0.5 mM ZnO NP for varying times and viability 
determined using PI uptake and flow cytometry.  Means  standard error from 
representative experiments are presented (n=3). 
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Figure 8. Differential cytotoxic effects of ZnO NP on primary immune cell subsets. A) 
PBMC were treated with varying concentrations (0.5 mM-10 mM) of 8 nm ZnO NP for 
24 h and viability of CD3
+ 
T cells, CD4
+
 T cells, B cells, NK cells, and monocytes 
present in PBMC cultures determined by monitoring PI uptake and flow cytometry. Data 
from three (CD3
+
, NK cell and monocyte) and four (B cell) independent experiments is 
presented, with error bars depicting standard error. Data presented for purified CD4
+
 T 
cells (>96%) is from one representative experiment done in triplicate with error bars 
depicting standard error.  Asterisks denote statistically significant (p < 0.05) differences 
between CD3
+
 T cells, B cells, NK cells and monocytes at indicated NP concentrations as 
determined using a repeated measures ANOVA. B) ZnO NP toxicity on purified human 
primary monocytes. Isolated CD14
+ 
monocytes were treated with varying concentrations 
of ZnO NP (0.0625 -1 mM) and viability assessed using the Alamar Blue cytotoxicity 
assay with error bars representing standard error (n=4). 
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Figure 9. TEM images of different sized ZnO nanoparticle made by varying the 
hydrolysis molar ratio. A) 4 nm sized ZnO NP made using a water to zinc acetate ratio of 
2.4. B) 8 nm sized ZnO NP made using a water to zinc acetate ratio of 6.1. C) 13 nm 
sized ZnO NP made using a water to zinc acetate ratio of 12.2. D) 20 nm sized ZnO NP 
made using a water to zinc acetate ratio of 36.6. E) Corresponding size distribution of the 
samples shown in panels A-D as determined by TEM. F) XRD patterns of the ZnO 
samples shown in panels A-D.  Reference data for wurtzite ZnO is shown along the 
bottom. 
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Figure 10. Effect of NP size on cytotoxicity. A) Purified human CD4
+
 T cells (>97% 
purity) were left untreated or incubated with three different sizes (4nm, 13nm, and 20 
nm) of ZnO NP at a final concentration of 5 mM. Following culture for 22-24 h, viability 
was determined using PI uptake and flow cytometry, n=4. B) Cytotoxicity studies in 
purified human CD4
+
 T cells were performed using varying concentrations (1-10 mM) of 
4nm and 20 nm sized ZnO NP, n=4.   Error bars depict standard error and asterisks 
indicate statistically significant differences (p < 0.05) as determined by repeated 
measures ANOVA.  
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Figure 11. Cellular production of ROS following ZnO NP exposure.  ROS generation 
was evaluated in primary T cells and monocytes and in the transformed Hut-78 T cell line 
following 18-24 h of ZnO NP exposure using the oxidation sensitive dye DCFH-DA and 
flow cytometry. A & C) Representative histograms depicting ROS production in primary 
T cells and monocytes.  Assays were performed using freshly obtained whole blood in 
which red blood cells were removed following NH4Cl lysis. T lymphocytes and 
monocytes were gated based on staining with fluorescently labeled CD3 and CD14 Ab 
and the oxidation product of DCFH-DA detected using the FL1 detector. B) Histogram 
depicting ROS production in the transformed Hut-78 T cell line.  In each histogram, the 
grey line depicts fluorescence in DCFH-DA loaded cells while the black line depicts 
fluorescence in DCFH-DA loaded cells treated with ZnO NP for 18 h (A & C) or 24 h 
(B).  Numbers in parentheses indicate the percentage of ROS positive cells. 
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Figure 12. NP size affects ROS production in PBMC. PBMC were treated with two 
different concentrations (5 mM and 10 mM) of 4 nm, 13 nm and 20 nm ZnO NP for 3 h 
and ROS production evaluated using a fluorescent microplate reader. Data from one 
representative experiment is shown (n = 3) and error bars depict standard error. Data was 
analyzed using a 2-way ANOVA and asterisks denote statistically significant differences 
as defined by p < 0.05. 
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Figure 13. Quenching of ROS rescues T cells and monocytes from ZnO NP-induced 
cytotoxicity. Purified peripheral blood CD14
+ 
monocytes ( 96% purity) and CD4+ T 
cells ( 95% purity) were pretreated for 4-6 h with 5 mM N-acetyl cysteine (NAC) or 
vehicle control and subsequently cultured with ZnO NP, or left untreated, for 22-24 h. 
Viability was assessed using the Alamar Blue cytotoxicity assay. A) Purified monocytes 
treated with 0.125 mM ZnO NP  5 mM NAC, n=3. B) Isolated CD4+ T cells  treated 
with 5 mM ZnO NP   5 mM NAC, n=3. Data for both T cells and monocytes was 
analyzed using a 2-way ANOVA; asterisks denote statistically significant differences (p 
< 0.05) and error bars depict standard error. 
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Figure 14. The activation of T cells promotes NP association. Primary CD4
+
 T cells 
(>96% purity) were left untreated or activated with immobilized CD3/CD28 antibodies 
and cultures concurrently treated with 5 mM FITC encapsulated ZnO NP for 4 h. Cells 
were stained using an ECD-labeled CD4 Ab. Using flow cytometry, 10 000 events gated 
on CD4
+
 cells were analyzed for changes in FITC fluorescence and data from a 
representative histogram is presented. A) Resting T cells cultured with FITC 
encapsulated NP and panel. B) Activated T cells cultured with FITC encapsulated NP. 
Inset numbers depict the percentage of FITC positive cells. The positioning of the 
quadrant on the x-axis was determined using T cells cultured without fluorescently 
labeled NP and set so 1% of cells appeared in quadrant 2. C) Depicts a dose-dependent 
increase in NP association with T cells, n = 3 with error bars depicting standard error. 
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Figure 15. Uptake of FITC-ZnO particles by Jurkat T cells. Confocal fluorescence 
microscopic images of Jurkat T cancer cells treated with 0.25 mM FITC-ZnO particle 
(green fluorescence) for 8 h and stained with a PE-conjugated Ab specific to CD3 cell 
surface protein (red fluorescence) with extensive washing to remove extracellular NP.  
Panel A depicts FITC-ZnO particles alone (after identical washing steps as samples 
containing cells) with an arrow indicating a typical particle of ~200 nm. Panels B-D show 
consecutive cell images/slices of a single cell. In panel C, an internalized particle of 
expected 200 nm size is indicated by an arrow and orthogonal viewing was used to 
confirm particle intracellular localization. 
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Figure 16. ZnO NP induce apoptosis in Jurkat T cells. Cells were left untreated, treated 
with 0.3 mM ZnO NP for 20 h, or treated with 100 nM okadaic acid for 20 h (positive 
control) and stained with a green fluorescent annexin V antibody to detect apoptotic 
membranes and the red fluorescent dye PI to detect permeable membranes using the 
Vybrant apoptosis assay kit #2 (Molecular Probes). Cells were visualized by confocal 
microscopy and representative images are shown. Panels A-C depicts control cells not 
treated with NP. Panel A shows control differential interference contrast (DIC image), 
panel B shows control DIC image with green and red fluorescence overlay, and panel C 
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shows control green and red fluorescence image. Panels D-G depict cells treated with NP; 
panel D shows NP treated DIC image, panel E shows NP treated DIC image with green 
and red fluorescence overly, panel F shows NP treated green and red fluorescence image, 
and panel G shows an additional green and red fluorescence image of NP treated cells of 
lower magnification. 
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Figure 17. Detection of apoptotic morphological changes in Jurkat cells treated with ZnO 
NP. Cells were left untreated (A), or treated with 100 nM okadaic acid for 20 h as a 
positive control for apoptosis (B), or treated with 0.3 mM ZnO NP for 20 h (C) and 
stained with acridine orange and visualized by fluorescent microscopy. Arrows indicate 
typical apoptotic cells characterized by a shrunken appearance and condensed or 
fragmented nuclei. 
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Figure 18. ZnO NP treatment increases pro-inflammatory cytokine production in 
PBMCs. Primary human peripheral mononuclear cells were left untreated or treated with 
three concentrations of 8 nm ZnO NP (0.05 mM, 0.1 mM and 0.2 mM), both alone or 
with the addition of exogenous IFN- (1000 U/mL) for 38 h. Cytokine production was 
evaluated by ELISA and measured in pg/mL. Data was analyzed using a 2-way ANOVA 
with error bars depicting standard error from the mean. Asterisks denote statistically 
significant differences as defined as p < 0.05. ** = significant differences between all 
treatment groups (including NT), * = significant differences compared to 0.05 mM and 
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NT. No significant differences were observed for any samples not primed with 
exogenous IFN-. 
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Figure 19. Effect of SnO2 NP and CeO2 NP on T cell viability. Purified human CD4
+
 T 
cells (> 97% purity) were left untreated or incubated with two different concentrations of 
either SnO2 NP or CeO2. Following culture for 22-24 h, viability was determined using PI 
uptake and flow cytometry, n=3 from one representative experiment and error bars depict 
standard error. A) T cells left untreated or treated with 5 mM SnO2 NP. B) T cells left 
untreated or treated with 5 mM CeO2 NP.  
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Table 1. Freshly isolated PBMC were treated with either 1mM or 5 mM of 8 nm sized 
ZnO NP and ROS production measured using the oxidation sensitive fluorescent probe, 
DCFH-DA.  Following NP treatment for 6 h or 20 h, cells were stained with fluorescently 
labeled CD3 (T cells) and CD14 (monocytes) Ab and loaded with DCFH-DA. Flow 
cytometry was used to simultaneously evaluate ROS production and distinguish T cells 
and monocytes present in PBMC cultures. Values represent the percentage of ROS 
producing cells ± standard error from the mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.              NP-induced ROS production 
 
Time *Cells 0 mM NP 1 mM NP 5 mM NP 
6h T cells 1.4%  0.1% 1.3%  0% ***ND 
6h mono 1.4%  0.13% 19.3%  2.6% ***ND 
20h T cells 6.5%  2.8% 3.4%  1.1% 38.5%  1.8% 
20h mono 8.1%  3.4% **<3% viable cells **<1% viable cells 
* CD3
+
 T cells and CD14
+
/CD3
-
 monocytes (monos) present in PBMCs  
** NP-induced cell destruction precludes collection of FS/SSC gated cellular events and subsequent 
ROS signal    
***Values not determined (ND) 
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Table 2. Freshly isolated PBMCs were left untreated or exposed to 5 mM FITC-
encapsulated ZnO NP for 16h. The cell mixture was then stained with fluorescently 
labeled CD3, CD4, CD19, CD14 Ab to identify subsets, washed to remove excess Ab and 
unbound NP, and the level of NP association determined based on FITC fluorescent 
signal using flow cytometry. Data was obtained by gating on 10 000 events, n=3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.                       NP association with various immune cells 
 
 Control (% / MFI)
a
 + FITC-NP (% / MFI)
b
 
CD3
+
 T cells 
CD4
+
 T cells 
CD19
+ 
B cells 
CD14
+
 Monocytes
 
1.79% / 1.15 
1.61% / 1.23 
2.0% / 2.85 
1.7% / 5.80 
84.2% / 9.84 
82.5% / 14.1 
78.1% / 9.61 
98.0% / 131.2 
a
Values shown represent the background autofluorescence signal for control cells (percent 
FITC positive cells/mean fluorescent intensity (MFI) 
b
The percentage of FITC positive cell and MFI for cells treated with FITC-doped ZnO 
NP  
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